

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2015/181756 A1

(43) International Publication Date  
3 December 2015 (03.12.2015)

(51) International Patent Classification:

*C07K 19/00* (2006.01) *C07K 14/16* (2006.01)  
*A61K 38/16* (2006.01) *C07K 14/705* (2006.01)  
*A61K 9/19* (2006.01) *C07K 7/06* (2006.01)  
*A61P 9/10* (2006.01) *C07K 7/08* (2006.01)

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/IB2015/053995

(22) International Filing Date:

28 May 2015 (28.05.2015)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/004,142 28 May 2014 (28.05.2014) US

(71) Applicant: NONO INC. [CA/CA]; 88 Strath Avenue, Toronto, Ontario M8X 1R5 (CA).


(72) Inventor: GARMAN, Jonathan David; 148 Lawrie Road, Thornhill, Ontario L4J8N1 (CA).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: CHLORIDE SALT OF TAT-NR2B9C



Formulations 1-3 from small scale 6

FIG. 7A, B

(57) Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neuro-traumatic conditions. The chloride salt of TAT-NR2B9c shows improved stability compared with the acetate salt form of prior formulations. Formulations of the chloride salt of TAT-NR2B9c are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.

## CHLORIDE SALT OF TAT-NR2B9c

### CROSS-REFERENCE TO RELATED APPLICATION

[001] This application is a non-provisional of US 62/004,142, filed May 28, 2014, incorporated by reference in its entirety for all purposes.

### REFERENCE TO SEQUENCE LISTING

[002] A sequence listing designated 446849SEQLIST.txt of 16,618 bytes created May 28, 2014 is incorporated by reference.

### BACKGROUND

[003] Tat-NR2B9c (also known as NA-1) is an agent that inhibits PSD-95, thus disrupting binding to N-methyl-D-aspartate receptors (NMDARs) and neuronal nitric oxide synthases (nNOS) and reducing excitotoxicity induced by cerebral ischemia. Treatment reduces infarction size and functional deficits. TAT-NR2B9c has undergone a successful phase II trial (see WO 2010144721 and Aarts et al., *Science* 298, 846-850 (2002), Hill et al., *Lancet Neurol.* 11:942 – 950 (2012)).

[004] Because TAT-NR2B9c is free of serious side effects, it can be administered when stroke or other ischemic conditions or hemorrhagic conditions is suspected without a diagnosis according to art-recognized criteria having been made to confirm that no hemorrhage is present. For example, TAT-NR2B9c can be administered at the location where the stroke or neurotrauma has occurred (e.g., in the patients' home) or in an ambulance transporting a subject to a hospital.

[005] TAT-NR2B9c has previously been described as a liquid composition of normal saline or phosphate buffered saline or a lyophilized composition from normal saline (WO2010144721).

### SUMMARY OF THE CLAIMED INVENTION

[006] The invention provides a chloride salt of a peptide which is TAT-NR2B9c (SEQ ID NO:6) or differs from TAT-NR2B9c by up to 5 amino acid substitutions, insertions or deletions, or any other peptide disclosed as an active agent herein. The chloride salt can be prepared by exchanging trifluoroacetate for chloride in a trifluoroacetate salt of TAT-NR2B9c. The chloride salt can also be prepared by exchanging trifluoroacetate for acetate and then acetate for chloride

starting from a trifluoroacetate salt of TAT-NR2B9c. Optionally, greater than 99% of anions in the salt are chloride.

[007] The invention further provides a prelyophilized formulation comprising a chloride salt as described above a buffer and a sugar. Optionally, the chloride salt is a chloride salt of TAT-NR2B9c. Optionally, the buffer is histidine and the sugar is trehalose and the pH is 6-7. Optionally, acetate and trifluoroacetate each comprise less than 1% of anions by weight in the formulation. Optionally, acetate and trifluoroacetate each comprise less than 0.1% by weight of anions in the formulation. Optionally, the chloride salt of the peptide is at a concentration of 70-120 mg/ml, the histidine is at a concentration of 15-100 mM, and the trehalose is at a concentration of 80-160 mM. Optionally, the chloride salt of the peptide is at a concentration of 70-120 mg/ml, the histidine is at a concentration of 20-100 mM, and the trehalose is at a concentration of 100-140 mM. Optionally, the Tat-NR2B9c is at a concentration of 70-120 mg/ml, the concentration of histidine 20-50 mM, and the concentration of trehalose is 100-140 mM. Optionally, the concentration of histidine is 20 mM and the concentration of trehalose is 100-200 mM, preferably 120 mM and the concentration of TAT-NR2B9c is 90 mg/ml.

[008] The invention further provides a lyophilized formulation prepared by lyophilizing any of the prelyophilized formulations described above. Optionally, acetate and trifluoroacetate each comprise less than 1% by weight of anions in the formulation. Optionally, acetate and trifluoroacetate each comprise less than 0.1% by weight of anions in the formulation.

[009] The invention further provides a reconstituted formulation prepared by combining any of the lyophilized formulations described above with an aqueous solution. Optionally, the aqueous solution is water or normal saline. Optionally, the volume of the reconstituted formulation is 3-6 times the volume of the prelyophilized formulation.

[0010] The invention further provides a reconstituted formulation comprising TAT-NR2B9c or other active agent described herein at concentration of 15-25 mg/ml, a buffer and a sugar. Optionally, the buffer is histidine at a concentration of 4-20 mM and the sugar is trehalose at a concentration of 20-30 mM and the pH is 6-7. Optionally, the reconstituted formulation of claim 19 wherein acetate and trifluoroacetate each comprise less than 1% by weight of anions in the formulation. Optionally, acetate and trifluoroacetate each comprise less than 0.1% by weight of anions in the formulation.

[0011] The invention further provides a method of preparing a formulation, comprising storing a lyophilized formulation sample as described above for at least a week at a temperature of at least 20°C; and reconstituting the lyophilized formulation. Optionally the lyophilized formulation is reconstituted in water or saline. Optionally, the method also includes administering the reconstituted formulation, optionally after further dilution in normal saline, to a patient. Optionally, the formulation is stored for at least a year. Optionally, the storage is at ambient temperature. Optionally, the storage includes periods in which the temperature exceeds 37°C. In some methods, the patient has stroke or traumatic injury to the CNS. In some methods, the lyophilized sample is stored in an ambulance. In some methods, the patient has a subarachnoid hemorrhage. In some methods, the patient is undergoing endovascular repair for an aneurysm.

#### BRIEF DESCRIPTIONS OF THE FIGURES

[0012] Figure 1: Graph shows the infarct area of the rat brain after 3PVO stroke following treatment with different formulations of TAT-NR2B9c.

[0013] Figures 2A, B: A) Bar graph demonstrating the stability of different TAT-NR2B9c formulations at -20°C and 40°C. Y axis represents purity of the TAT-NR2B9c after 1 week at the storage temperature as measured by % total area using RP-HPLC. B) same data as A, but sorted by buffer and pH.

[0014] Figure 3: Bar graph demonstrating the stability (by HPLC) of 20 mg/ml TAT-NR2B9c in Histidine buffer, pH 6.5, in the presence of different bulking agents and salt at -20oC and 40oC.

[0015] Figures 4A, B: Differential scanning calorimetry graphs of 20 mg/ml TAT-NR2B9c in histidine buffer pH 6.5 in the presence of Mannitol (A) or Mannitol and NaCl (B).

[0016] Figures 5A, B: Differential scanning calorimetry graphs of 20 mg/ml TAT-NR2B9c in histidine buffer pH 6.5 in the presence of Trehalose (A) or Trehalose and NaCl (B).

[0017] Figures 6A, B: Differential scanning calorimetry graph of 20 mg/ml TAT-NR2B9c in histidine buffer pH 6.5 in the presence of Dextran-40 (A) or Dextran-40 and NaCl (B).

[0018] Figures 7A, B: A) Cake appearance following lyophilization of 3 mL of 90 mg/ml TAT-NR2B9c in 100 mM Histidine pH 6.5 with 120 mM Trehalose. B). Cake appearance of alternative TAT-NR2B9c formulations with different amounts of histidine and trehalose.

## DEFINITIONS

[0019] As well as active ingredients, lyophilized formulations can include one or more of the following classes of components. The classes are not mutually exclusive; in other words the same agent can component can fall within multiple classes.

[0020] A "bulking agent" provides structure to a freeze-dried peptide. Bulking agents include, mannitol, trehalose, dextran-40, glycine, lactose, sorbitol, and sucrose among others. In addition to providing a pharmaceutically elegant cake, bulking agents may also impart useful qualities in regard to modifying the collapse temperature, providing freeze-thaw protection, glass transition temperature and enhancing the protein stability over long-term storage. These agents can also serve as tonicity modifiers.

[0021] A buffer is an agent that maintains the solution pH in an acceptable range prior to lyophilization. A preferred buffer is histidine. Other buffers include succinate (sodium or potassium), histidine, citrate (sodium), gluconate, acetate, phosphate, Tris and the like. Preferred buffers are effective in a pH range from about 5.5 to about 7 or about 6 to about 7; preferably a pH of about 6.5. Examples of buffers that control the pH in this range include succinate (such as sodium succinate), gluconate, histidine, citrate and other organic acid buffers.

[0022] A "cryoprotectant" provides stability to a peptide against freezing-induced stresses, presumably by being preferentially excluded from the protein surface. It may also offer protection during primary and secondary drying, and long-term product storage. Examples are polymers such as dextran and polyethylene glycol; sugars (including sugar alcohols) such as sucrose, glucose, trehalose, and lactose; and surfactants such as polysorbates; and amino acids such as glycine, arginine, and serine.

[0023] A lyoprotectant provides stability to the peptide during the drying or 'dehydration' process (primary and secondary drying cycles), presumably by providing an amorphous glassy matrix and by binding with the protein through hydrogen bonding, replacing the water molecules that are removed during the drying process. This helps to maintain the peptide conformation,

minimize peptide degradation during the lyophilization cycle and improve the long-term product stability. Examples include polyols or sugars such as sucrose and trehalose.

[0024] To the extent not already mentioned, other stabilizers or inhibitors of degradations can be included deamidation inhibitors, surfactants, some common ones are fatty acid esters of sorbitan polyethoxylates (e.g., polysorbate 20 or polysorbate 80), poloxamer 188, and detergents.

[0025] The terms "lyophilization," "lyophilized," and "freeze-dried" refer to a process by which the material to be dried is first frozen and then the ice or frozen solvent is removed by sublimation in a vacuum environment.

[0026] A "pharmaceutical formulation" or composition is a preparation that permits an active agent to be effective, and lacks additional components which are toxic to the subjects to which the formulation would be administered.

[0027] "Reconstitution time" is the time that is required to rehydrate a lyophilized formulation with a solution to solution which is free of particles to the naked eye.

[0028] A "stable" lyophilized peptide formulation is one with no significant changes observed at 20° C for at least one week, month, or more preferably at least three months, at least six months or a year. Changes are considered insignificant if no more than 10%, preferably 5%, of peptide is degraded as measured by SEC-HPLC. The rehydrated solution is colorless, or clear to slightly opalescent by visual analysis. The concentration, pH and osmolality of the formulation have no more than +/-10% change after storage. Potency is within 70-130%, preferably 80-120% or sometimes 80-100% of a freshly prepared control sample. No more than 10%, preferably 5% of clipping is observed. No more than 10%, preferably 5% of aggregation is formed. Stability can be measured by various methods reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, N.Y., Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10:29-90 (1993).

[0029] The term "isotonic" means that the formulation of interest has essentially the same osmotic pressure as human blood. Isotonic formulations will generally have an osmotic pressure from about 270-328 mOsm. Slightly hypotonic pressure is 250-269 and slightly hypertonic pressure is 328-350 mOsm. Osmotic pressure can be measured, for example, using a vapor pressure or ice-freezing type osmometer.

[0030] Tonicity Modifiers: Salts (NaCl, KCl, MgCl<sub>2</sub>, CaCl<sub>2</sub>) can be used as tonicity modifiers to control osmotic pressure. In addition, cryoprotectants/lyoprotectants and/or bulking agents such as sucrose, mannitol, or glycine can serve as tonicity modifiers.

[0031] Numeric values such as concentrations or pH's are given within a tolerance reflecting the accuracy with which the value can be measured. Unless the context requires otherwise, fractional values are rounded to the nearest integer. Unless the context requires otherwise, recitation of a range of values means that any integer or subrange within the range can be used.

[0032] The terms "disease" and "condition" are used synonymously to indicate any disruption or interruption of normal structure or function in a subject.

#### DETAILED DESCRIPTION

##### I. General

[0033] Peptides synthesized by solid state methods are typically produced as trifluoroacetate salts because trifluoroacetic acid (TFA) is used for deprotection of peptides and/or removal of peptides from resins. For pharmaceutical use, the trifluoroacetate is usually replaced with acetate as a counterion because acetate is nontoxic and the replacement of trifluoroacetate by acetate is straightforward. Such has been the case for the peptide TAT-NR2B9c synthesized to-date as described in WO2010144721 or PCT/US2013/071755 and elsewhere.

[0034] Acetate is often a preferred counterion for pharmaceutically peptides because trifluoroacetate can be exchanged for acetate with a minor change in the typical purification process of a peptide resulting from solid phase synthesis in which the final wash is performed with acetic acid instead of trifluoroacetic acid followed by elution with acetonitrile. Occasionally other counterions are used instead. For example, chloride is sometimes used for poorly soluble peptides because it improves their solubility. However, conversion of trifluoroacetate or acetate to chloride results in loss of some peptide. Moreover, presence of HCl resulting from chloride exchange has been reported to modify the structure and reduce the thermal stability of some peptides (Biochemistry, 5th edition, Berg et al. eds, Freeman; 2002); J Pept Sci. 2007 Jan;13(1):37-43). TAT-NR2B9c is already a highly soluble peptide as an acetate salt. Accordingly, replacement of trifluoroacetate or acetate salt with chloride would have appeared to have the disadvantages of decreased yield and possible reduced stability without any compensating benefit.

[0035] Surprisingly it has been found that a chloride salt of TAT-NR2B9c confers significantly greater stability in the lyophilized form than an acetate salt of TAT-NR2B9c in the same formulation, or an acetate salt of TAT-NR2B9c lyophilized from saline. The chloride salt can remain sufficiently stable for clinical use even with storage at summer time ambient temperatures reaching or even exceeding 37°C for several years. The greater stability of the chloride salt over acetate more than compensates for any greater effort or reduced yield required in replacing trifluoroacetate as a salt. The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c as a chloride salt. Such formulations are stable at ambient temperature (e.g., at least 20°C) thus facilitating maintenance of supplies of such a formulation in ambulances or the like or with emergency personnel for administration at the scene of illness or accident or between such scene and a medical facility.

[0036] Lyophilized formulations are prepared from a prelyophilized formulation comprising an active agent, a buffer, a bulking agent and water. Other components, such as cryo or lyopreservatives, a tonicity agent pharmaceutically acceptable carriers and the like may or may be present. A preferred active agent is a chloride salt of TAT-NR2B9c. A preferred buffer is histidine. A preferred bulking agent is trehalose. Trehalose also serves as a cryo and lyo-preservative. An exemplary prelyophilized formulation comprises the active agent (e.g., chloride salt of TAT-NR2B9c), histidine (10-100 mM, 15-100 mM 15-80 mM, 40-60 mM or 15-60 mM, for example, 20 mM or optionally 50 mM, or 20-50mM)) and trehalose (50-200 mM, preferably 80-160 mM, 100-140 mM, more preferably 120 mM). The pH is 5.5 to 7.5, more preferably, 6-7, more preferably 6.5. The concentration of active agent (e.g., chloride salt of TAT-NR2B9c) is 20-200 mg/ml, preferably 50-150 mg/ml, more preferably 70-120 mg/ml or 90 mg/ml. Thus, an exemplary prelyophilized formulation is 20 mM histidine, 120 mM trehalose, and 90 mg/ml chloride salt of TAT-NR2B9c. Optionally an acetylation scavenger, such as lysine can be included, as described in co-pending application 057769-446850, to further reduce any residual acetate or trifluoroacetate in the formulation

[0037] After lyophilization, lyophilized formulations have a low-water content, preferably from about 0%-5% water, more preferably below 2.5% water by weight. Lyophilized formulations can be stored in a freezer (e.g., -20 or -70° C), in a refrigerator (0-4° C) or at room temperature (20-25° C).

[0038] Active agents are reconstituted in an aqueous solution, preferably water for injection or optionally normal saline (0.8-1.0% saline and preferably 0.9% saline). Reconstitution can be to the same or a smaller or larger volume than the prelyophilized formulation. Preferably, the volume is larger post-reconstitution than before (e.g., 3-6 times larger). For example, a prelyophilization volume of 3-5 ml can be reconstituted as a volume of 10 mL, 12 mL, 13.5 mL, 15 mL or 20 mL or 10-20 mL among others. After reconstitution, the concentration of histidine is preferably 2-20 mM, e.g., 2-7 mM, 4.0-6.5 mM, 4.5mM or 6 mM; the concentration of trehalose is preferably 15-45 mM or 20-40 mM or 25-27 mM or 35-37 mM. The concentration of lysine is preferably 100-300 mM, e.g., 150-250mM, 150-170 mM or 210-220 mM. The active agent is preferably at a concentration of 10-30 mg/ml, for example 15-30, 18-20, 20 mg/ml of active agent (e.g., TAT-NR2B9c) or 25-30, 26-28 or 27 mg/mL active agent. An exemplary formulation after reconstitution has 4-5 mM histidine, 26-27 mM trehalose, 150-170 mM lysine and 20 mg/ml TAT-NR2B9c (with concentrations rounded to the nearest integer). A second exemplary formulation after reconstitution has 5-7 mM histidine, 35-37 mM trehalose, 210-220 mM lysine and 26-28 mg/ml TAT-NR2B9c (with concentrations rounded to the nearest integer). The reconstituted formulation can be further diluted before administration such as by adding into a fluid bag containing normal saline for intravenous infusion.

[0039] Any description of a formulation as comprising or including (or similar terminology) specified components should be understood as alternatively or additional describing a formulation consisting of or consisting essentially of those specified components.

[0040] Methods of freeze drying are set forth, for example, in Methods in Enzymology, Vol. 22, Pages 33-39, Academic Press, New York (1971); and in Freeze-Drying, E. W. Flosdorff, Rheinhold, New York (1949). TAT-NR2B9c is preferably lyophilized in the same vial as that in which it will be reconstituted for use. An aqueous solution of TAT-NR2B9c is added to the vial optionally after filtering through a sterilizing filtration system, such as a 0.22 micron filter standardly used for peptides. Formulations can be lyophilized in a controlled cycle, such as described in the Examples. A prelyophilized formulation can be placed in a vial, and lyophilized at reduced temperature and pressure. After lyophilization, vials can be sealed. For use, the lyophilizate is reconstituted with water for injection, normal saline or other pharmaceutically acceptable carrier or diluent.

[0041] A variety of containers are suitable for lyophilization. A container should be able to withstand the outside pressure when the container is sealed and stored under partial vacuum. The container should be made of a material that allows a reasonable transfer of heat from outside to inside. The size of the container should be such that the solution to be lyophilized occupies not more than 20% of the useful volume or may be overfilled with an excess, in accord with then-prevailing USP recommendations for the volume in a container. For example, a 0.5 ml solution may be filled in a 3 ml vial. The vials may be made of glass e.g. borosilicate, or plastic, e.g. polypropylene.

[0042] Glass bottles commonly used for lyophilizing biological materials can be used. Another suitable container is a two-compartment syringe wherein one compartment contains the lyophilized TAT-NR2B9c peptide cake and the other compartment contains the aqueous diluent. After lyophilization is complete, the vacuum within the vials or ampules may be released by filling the system with an inert gas, stoppered in place using standard equipment and then crimp sealed. Such a method will ensure a sterile final product. Other two-part solutions such as a bag with a breakable seal between the lyophilized drug compartment and the diluent can be used as well.

## II. Active Agents

[0043] Although much of the description refers to the active agent TAT-NR2B9c for purposes of exemplification, other active agents as described below can be prepared as chloride salts or formulated according to the principles described for TAT-NR2B9c. Specific concentrations given for TAT-NR2B9c can be used as is for other agents or converted to give equimolar concentrations of the other agent and TAT-NR2B9c.

[0044] Active agents inhibit interaction between PSD-95 and one or more NMDARs (e.g., 2A, 2B, 2C or 2D) or nNOS (e.g., Swiss-Prot P29475) by binding to PSD-95. Such agents are useful for reducing one or more damaging effects of stroke and other neurological conditions mediated at least in part by NMDAR excitotoxicity. Such agents include peptides having an amino acid sequence including or based on the PL motif of a NMDA Receptor or PDZ domain of PSD-95. Such peptides can also inhibit interactions between PSD-95 and nNOS and other glutamate receptors (e.g., kainite receptors or AMPA receptors), such as KV1.4 and GluR6. Preferred peptides inhibit interaction between PDZ domains 1 and 2 of postsynaptic density-95 protein (PSD-95)(human amino acid sequence provided by Stathakism, Genomics 44(1):71-82 (1997))

and the C-terminal PL sequence of one or more NMDA Receptor 2 subunits including the NR2B subunit of the neuronal N-methyl-D-aspartate receptor (Mandich et al., *Genomics* 22, 216-8 (1994)). NMDAR2B has GenBank ID 4099612, a C-terminal 20 amino acids FNGSSNGHVYEKLSSIESDV (SEQ ID NO:11) and a PL motif ESDV (SEQ ID NO:12). Preferred peptides inhibit the human forms of PSD-95 and human NMDAR receptors. However, inhibition can also be shown from species variants of the proteins. A list of NMDA and glutamate receptors that can be used appears below:

#### NMDA Receptors With PL Sequences

Name	GI or Acc#	C-terminal 20mer sequence	C-terminal 4mer sequence	PL?	internal PL ID
NMDAR1	307302	HPTDITGPLNLSDPSVST VV (SEQ ID NO:13)	STVV (SEQ ID NO:27)	X	AA216
NMDAR1-1	292282	HPTDITGPLNLSDPSVST VV (SEQ ID NO:13)	STVV (SEQ ID NO:27)	X	AA216
NMDAR1-4	472845	HPTDITGPLNLSDPSVST VV (SEQ ID NO:13)	STVV (SEQ ID NO:27)	X	AA216
NMDAR1-3b	2343286	HPTDITGPLNLSDPSVST VV (SEQ ID NO:13)	STVV (SEQ ID NO:27)	X	AA216
NMDAR1-4b	2343288	HPTDITGPLNLSDPSVST VV (SEQ ID NO:13)	STVV (SEQ ID NO:27)	X	AA216
NMDAR1-2	11038634	RRAIEREEGQLQLCSRH RES (SEQ ID NO:14)	HRES (SEQ ID NO:28)		
NMDAR1-3	11038636	RRAIEREEGQLQLCSRH RES (SEQ ID NO:14)	HRES (SEQ ID NO:28)		
NMDAR2C	6006004	TQGFPGPCTWRRRISSLES EV (SEQ ID NO:15)	ESEV (SEQ ID NO:29)	X	AA180
NMDAR3	560546	FNGSSNGHVYEKLSSIES DV (SEQ ID NO:11)	ESDV (SEQ ID NO:12)	X	AA34.1
NMDAR3A	17530176	AVSRKTELEEYQRTSRT CES (SEQ ID NO:16)	TCES (SEQ ID NO:30)		
NMDAR2B	4099612	FNGSSNGHVYEKLSSIES	ESDV	X	

Name	GI or Acc#	C-terminal 20mer sequence	C-terminal 4mer sequence	PL?	internal PL ID
		DV (SEQ ID NO:11)	(SEQ ID NO:12)		
NMDAR2A	558748	LNSCSNRRVYKKMPSIE SDV (SEQ ID NO:17)	ESDV (SEQ ID NO:12)	X	AA34.2
NMDAR2D	4504130	GGDLGTRRGSAHFSSLE SEV (SEQ ID NO:18)	ESEV (SEQ ID NO:29)	X	
Glutamate receptor delta 2	AF009014	QPTPTLGLNLGNDPDRG TSI (SEQ ID NO:19)	GTSI (SEQ ID NO:31)	X	
Glutamate receptor 1	I28953	MQSIPCMSHSSGMPPLGA TGL (SEQ ID NO:20)	ATGL (SEQ ID NO:32)	X	
Glutamate receptor 2	L20814	QNFATYKEGYNVYGIESTVKI (SEQ ID NO:21)	SVKI (SEQ ID NO:33)	X	
Glutamate receptor 3	AF167332	QNYATYREGYNVYGTESVKI (SEQ ID NO:22)	SVKI (SEQ ID NO:33)	X	
Glutamate receptor 4	U16129	HTGTAIRQSSGLAVIASDLP (SEQ ID NO:23)	SDLP (SEQ ID NO:34)		
Glutamate receptor 5	U16125	SFTSILTCHQRRTQRKETVA (SEQ ID NO:24)	ETVA (SEQ ID NO:35)	X	
Glutamate receptor 6	U16126	EVINMHTFNDRRLPGKETMA (SEQ ID NO:25)	ETMA (SEQ ID NO:36)	X	

[0045] Peptides can include or be based on a PL motif from the C-terminus of any of the above subunits and have an amino acid sequence comprising [S/T]-X-[V/L]. This sequence preferably occurs at the C-terminus of the peptides of the invention. Preferred peptides have an amino acid sequence comprising [E/D/N/Q]-[S/T]-[D/E/Q/N]-[V/L] (SEQ ID NO:38) at their C-terminus. Exemplary peptides comprise: ESDV (SEQ ID NO:12), ESEV (SEQ ID NO:29), ETDV (SEQ ID NO:39), ETEV (SEQ ID NO:40), DTDV (SEQ ID NO:41), and DTEV (SEQ ID NO:42) as the C-terminal amino acids. Two particularly preferred peptides are KLSSIESDV (SEQ ID NO:5), and KLSSIETDV (SEQ ID NO:43). Such peptides usually have 3-25 amino acids (without an internalization peptide), peptide lengths of 5-10 amino acids, and particularly 9

amino acids (also without an internalization peptide) are preferred. In some such peptides, all amino acids are from the C-terminus of an NMDA receptor (not including amino acids from an internalization peptide).


[0046] Peptides and peptidomimetics of the invention can contain modified amino acid residues for example, residues that are N-alkylated. N-terminal alkyl modifications can include e.g., N-Methyl, N-Ethyl, N-Propyl, N-Butyl, N-Cyclohexylmethyl, N-Cyclyhexylethyl, N-Benzyl, N-Phenylethyl, N-phenylpropyl, N-(3, 4-Dichlorophenyl)propyl, N-(3,4-Difluorophenyl)propyl, and N-(Naphthalene-2-yl)ethyl).

[0047] Bach, J. Med. Chem. 51, 6450-6459 (2008) and WO 2010/004003 have described a series of analogs of NR2B9c (SEQ ID NO:6). PDZ-binding activity is exhibited by peptides having only three C-terminal amino acids (SDV). Bach also reports analogs having an amino acid sequence comprising or consisting of X<sub>1</sub>tSX<sub>2</sub>V (SEQ ID NO:68), wherein t and S are alternative amino acids, X<sub>1</sub> is selected from among E, Q, and A, or an analogue thereof, X<sub>2</sub> is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analog thereof. Optionally the peptide is N-alkylated in the P3 position (third amino acid from C-terminus, i.e. position occupied by tS). The peptide can be N-alkylated with a cyclohexane or aromatic substituent, and further comprises a spacer group between the substituent and the terminal amino group of the peptide or peptide analogue, wherein the spacer is an alkyl group, preferably selected from among methylene, ethylene, propylene and butylene. The aromatic substituent can be a naphthalen-2-yl moiety or an aromatic ring substituted with one or two halogen and/or alkyl group.

[0048] Other modifications can also be incorporated without adversely affecting the activity and these include substitution of one or more of the amino acids in the natural L-isomeric form with amino acids in the D-isomeric form. Thus, any amino acid naturally occurring in the L-configuration (which can also be referred to as the R or S, depending upon the structure of the chemical entity) can be replaced with the amino acid of the same chemical structural type or a peptidomimetic, but of the opposite chirality, generally referred to as the D-amino acid, but which can additionally be referred to as the R- or S-form. Thus, a peptidomimetic may include 1, 2, 3, 4, 5, at least 50%, or all D-amino acid resides. A peptidomimetic containing some or all D residues is sometimes referred to an “inverso” peptide.

[0049] Peptidomimetics also include retro peptides. A retro peptide has a reverse amino acid sequence. Peptidomimetics also include retro inverso peptides in which the order of amino acids is reversed from so the originally C-terminal amino acid appears at the N-terminus and D-amino acids are used in place of L-amino acids. WO 2008/014917 describes a retro-inverso analog of Tat-NR2B9c having the amino acid sequence vdseisslk-rrrqrrkkrgyin (SEQ ID NO:69) (lower case letters indicating D amino acids), and reports it to be effective inhibiting cerebral ischemia. Another effective peptide described herein is Rv-Tat-NR2B9c (RRRQRRKKRGYKLSSIESDV; SEQ ID NO:70).

[0050] A linker, e.g., a polyethylene glycol linker, can be used to dimerize the active moiety of the peptide or the peptidomimetic to enhance its affinity and selectivity towards proteins containing tandem PDZ domains. See e.g., Bach et al., (2009) *Angew. Chem. Int. Ed.* 48:9685-9689 and WO 2010/004003. A PL motif-containing peptide is preferably dimerized via joining the N-termini of two such molecules, leaving the C-termini free. Bach further reports that a pentamer peptide IESDV (SEQ ID NO:71) from the C-terminus of NMDAR 2B was effective in inhibiting binding of NMDAR 2B to PSD-95. IETDV (SEQ ID NO:73) can also be used instead of IESDV. Optionally, about 2-10 copies of a PEG can be joined in tandem as a linker. Optionally, the linker can also be attached to an internalization peptide or lipidated to enhance cellular uptake. Examples of illustrative dimeric inhibitors are shown below (see Bach et al., *PNAS* 109 (2012) 3317-3322). Any of the PSD-95 inhibitors disclosed herein can be used instead of IETDV, and any internalization peptide or lipidating moiety can be used instead of tat. Other linkers to that shown can also be used.



[0051] IETAV is assigned SEQ ID NO:26, YGRKKRRQRRR SEQ ID NO:2, and rrrqrrkkr, SEQ ID NO:10, lower case letters indicated D-amino acids.

[0052] Appropriate pharmacological activity of peptides, peptidomimetics or other agent can be confirmed if desired, using previously described rat models of stroke before testing in the primate and clinical trials described in the present application. Peptides or peptidomimetics can also be screened for capacity to inhibit interactions between PSD-95 and NMDAR 2B using assays described in e.g., US 20050059597, which is incorporated by reference. Useful peptides typically have IC<sub>50</sub> values of less than 50  $\mu$ M, 25  $\mu$ M, 10  $\mu$ M, 0.1  $\mu$ M or 0.01  $\mu$ M in such an assay. Preferred peptides typically have an IC<sub>50</sub> value of between 0.001-1  $\mu$ M, and more preferably 0.001-0.05, 0.05-0.5 or 0.05 to 0.1  $\mu$ M. When a peptide or other agent is characterized as inhibiting binding of one interaction, e.g., PSD-95 interaction to NMDAR2B, such description does not exclude that the peptide or agent also inhibits another interaction, for example, inhibition of PSD-95 binding to nNOS.

[0053] Peptides such as those just described can optionally be derivatized (e.g., acetylated, phosphorylated, myristoylated, geranylated, pegylated and/or glycosylated) to improve the binding affinity of the inhibitor, to improve the ability of the inhibitor to be transported across a cell membrane or to improve stability. As a specific example, for inhibitors in which the third residue from the C-terminus is S or T, this residue can be phosphorylated before use of the peptide.

[0054] A pharmacological agent can be linked to an internalization peptide to facilitate uptake into cells and/or across the blood brain barrier. Internalization peptides are a well-known class of relatively short peptides that allow many cellular or viral proteins to traverse membranes. Internalization peptides, also known as cell membrane transduction peptides or cell penetrating peptides can have e.g., 5-30 amino acids. Such peptides typically have a cationic charge from an above normal representation (relative to proteins in general) of arginine and/or lysine residues that is believed to facilitate their passage across membranes. Some such peptides have at least 5, 6, 7 or 8 arginine and/or lysine residues. Examples include the antennapedia protein (Bonfanti, Cancer Res. 57, 1442-6 (1997)) (and variants thereof), the tat protein of human immunodeficiency virus, the protein VP22, the product of the UL49 gene of herpes simplex virus type 1, Penetratin, SynB1 and 3, Transportan, Amphipathic, gp41NLS, polyArg, and several

plant and bacterial protein toxins, such as ricin, abrin, modeccin, diphtheria toxin, cholera toxin, anthrax toxin, heat labile toxins, and *Pseudomonas aeruginosa* exotoxin A (ETA). Other examples are described in the following references (Temsamani, Drug Discovery Today, 9(23):1012-1019, 2004; De Coupade, Biochem J., 390:407-418, 2005; Saalik Bioconjugate Chem. 15: 1246-1253, 2004; Zhao, Medicinal Research Reviews 24(1):1-12, 2004; Deshayes, Cellular and Molecular Life Sciences 62:1839-49, 2005); Gao, ACS Chem. Biol. 2011, 6, 484-491, SG3 (RLSGMNEVLSFRWL (SEQ ID NO:9)), Stalmans PLoS ONE 2013, 8(8) e71752, 1-11 and supplement; Figueiredo et al., IUBMB Life 66, 182-194 (2014); Copolovici et al., ACS Nano, 8, 1972-94 (2014); Lukowski Biotech J. 8, 918-930 (2013); Stockwell, Chem. Biol. Drug Des. 83, 507-520 (2014); Stanzl et al. Accounts. Chem. Res/ 46, 2944-2954 (2013); (all incorporated by reference).

[0055] A preferred internalization peptide is tat from the HIV virus. A tat peptide reported in previous work comprises or consists of the standard amino acid sequence YGRKKRRQRRR (SEQ ID NO:2) found in HIV Tat protein. If additional residues flanking such a tat motif are present (beside the pharmacological agent) the residues can be for example natural amino acids flanking this segment from a tat protein, spacer or linker amino acids of a kind typically used to join two peptide domains, e.g., gly (ser)<sub>4</sub> (SEQ ID NO:44), TGEKP (SEQ ID NO:45), GGRRGGGS (SEQ ID NO:46), or LRQRDGERP (SEQ ID NO:47) (see, e.g., Tang et al. (1996), J. Biol. Chem. 271, 15682-15686; Hennecke et al. (1998), Protein Eng. 11, 405-410)), or can be any other amino acids that do not significantly reduce capacity to confer uptake of the variant without the flanking residues. Preferably, the number of flanking amino acids other than an active peptide does not exceed ten on either side of YGRKKRRQRRR (SEQ ID NO:2). One suitable tat peptide comprising additional amino acid residues flanking the C-terminus of YGRKKRRQRRR (SEQ ID NO:2) is YGRKKRRQRRRPQ (SEQ ID NO:48). However, preferably, no flanking amino acids are present. Other tat peptides that can be used include GRKKRRQRRRPQ (SEQ ID NO:4) and GRKKRRQRRRP (SEQ ID NO:72).

[0056] Variants of the above tat peptide having reduced capacity to bind to N-type calcium channels are described by WO/2008/109010. Such variants can comprise or consist of an amino acid sequence XGRKKRRQRRR (SEQ ID NO:49), in which X is an amino acid other than Y or nothing (in which case G is a free N-terminal residue). A preferred tat peptide has the N-

terminal Y residue substituted with F. Thus, a tat peptide comprising or consisting of FGRKKRRQRRR (SEQ ID NO:3) is preferred. Another preferred variant tat peptide consists of GRKKRRQRRR (SEQ ID NO:1). Another preferred tat peptide comprises or consists of RRRQRRKKRG or RRRQRRKKRGY (amino acids 1-10 or 1-11 of SEQ ID NO:70). Other tat derived peptides that facilitate uptake of a pharmacological agent without inhibiting N-type calcium channels include those presented below.

X-FGRKKRRQRRR (F-Tat) (SEQ ID NO:8)
X-GKKKKQKKK (SEQ ID NO:50)
X-RKKRRQRRR (SEQ ID NO:51)
X-GAKKRRQRRR (SEQ ID NO:52)
X-AKKRRQRRR (SEQ ID NO:53)
X-GRKARRQRRR (SEQ ID NO:54)
X-RKARRQRRR (SEQ ID NO:55)
X-GRKKARQRRR (SEQ ID NO:56)
X-RKKARQRRR (SEQ ID NO:57)
X-GRKKRQARR (SEQ ID NO:58)
X-RKKRQARR (SEQ ID NO:59)
X-GRKKRQRAR (SEQ ID NO:60)
X-RKRRQRAR (SEQ ID NO:61)
X-RRPQQPQQPQQ (SEQ ID NO:62)
X-RRARRARRARR (SEQ ID NO:63)
X-RRRARRARRARR (SEQ ID NO:64)
X-RRRPRRRPQQ (SEQ ID NO:65)
X-RRPQQPQQ (SEQ ID NO:66)
X-RRARRARR (SEQ ID NO:67)

[0057] X can represent a free amino terminus, one or more amino acids, or a conjugated moiety. Internalization peptides can be used in inverso or retro or inverso retro form with or without the linked peptide or peptidomimetic being in such form. For example, a preferred chimeric peptide has an amino acid sequence comprising or consisting of YGRKKRRQRRR-KLSSIESDV (SEQ ID NO:6, also known as TAT-NR2B9c or Tat-NR2B9c), or YGRKKRRQRRR-KLSSIETDV (SEQ ID NO:7). Other preferred chimeric peptides differ from SEQ ID NO:6 or NO:7 by up to 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions (internal or at the ends). Other preferred peptides include RRRQRRKKRGY-KLSSIESDV (SEQ ID NO:70, also known as

RvTat-NR2B9c or having an amino acid sequence comprising or consisting of RRRQRRKKRGY-KLSSIETDV (SEQ ID NO:37).

[0058] Internalization peptides can be attached to pharmacological agents by conventional methods. For example, the agents can be joined to internalization peptides by chemical linkage, for instance via a coupling or conjugating agent. Numerous such agents are commercially available and are reviewed by S. S. Wong, Chemistry of Protein Conjugation and Cross-Linking, CRC Press (1991). Some examples of cross-linking reagents include J-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) or N,N'-(1,3-phenylene) bismaleimide; N,N'-ethylene-bis-(iodoacetamide) or other such reagent having 6 to 11 carbon methylene bridges (which are relatively specific for sulfhydryl groups); and 1,5-difluoro-2,4-dinitrobenzene (which forms irreversible linkages with amino and tyrosine groups). Other cross-linking reagents include p,p'-difluoro-m, m'-dinitrodiphenylsulfone (which forms irreversible cross-linkages with amino and phenolic groups); dimethyl adipimidate (which is specific for amino groups); phenol-1,4-disulfonylchloride (which reacts principally with amino groups); hexamethylenediisocyanate or diisothiocyanate, or azophenyl-p-diisocyanate (which reacts principally with amino groups); glutaraldehyde (which reacts with several different side chains) and disdiazobenzidine (which reacts primarily with tyrosine and histidine).

[0059] For pharmacological agents that are peptides attachment to an internalization peptide can be achieved by generating a fusion protein comprising the peptide sequence fused, preferably at its N-terminus, to an internalization peptide.

[0060] Instead of or as well as linking a peptide (or other agent) inhibiting PSD-95 to an internalization peptide, such a peptide can be linked to a lipid (lipidation) to increase hydrophobicity of the conjugate relative to the peptide alone and thereby facilitate passage of the linked peptide across cell membranes and/or across the brain barrier. Lipidation is preferably performed on the N-terminal amino acid but can also be performed on internal amino acids, provided the ability of the peptide to inhibit interaction between PSD-95 and NMDAR 2B is not reduced by more than 50%. Preferably, lipidation is performed on an amino acid other than one of the four most C-terminal amino acids. Lipids are organic molecules more soluble in ether than water and include fatty acids, glycerides and sterols. Suitable forms of lipidation include myristoylation, palmitoylation or attachment of other fatty acids preferably with a chain length of

10-20 carbons, such as lauric acid and stearic acid, as well as geranylation, geranylgeranylation, and isoprenylation. Lipidations of a type occurring in posttranslational modification of natural proteins are preferred. Lipidation with a fatty acid via formation of an amide bond to the alpha-amino group of the N-terminal amino acid of the peptide is also preferred. Lipidation can be by peptide synthesis including a prelipidated amino acid, be performed enzymatically *in vitro* or by recombinant expression, by chemical crosslinking or chemical derivatization of the peptide. Amino acids modified by myristylation and other lipid modifications are commercially available.

[0061] Lipidation preferably facilitates passage of a linked peptide (e.g., KLSSIESDV (SEQ ID NO:5), or KLSSIETDV (SEQ ID NO:43)) across a cell membrane and/or the blood brain barrier without causing a transient reduction of blood pressure as has been found when a standard tat peptide is administered at high dosage (e.g., at or greater than 3 mg/kg), or at least with smaller reduction than the same peptide linked to a standard tat peptide.

[0062] Pharmacologic peptides, optionally fused to tat peptides, can be synthesized by solid phase synthesis or recombinant methods. Peptidomimetics can be synthesized using a variety of procedures and methodologies described in the scientific and patent literature, e.g., Organic Syntheses Collective Volumes, Gilman et al. (Eds) John Wiley & Sons, Inc., NY, al-Obeidi (1998) Mol. Biotechnol. 9:205-223; Hruby (1997) Curr. Opin. Chem. Biol. 1:114-119; Ostergaard (1997) Mol. Divers. 3:17-27; Ostresh (1996) Methods Enzymol. 267:220-234.

### III. Salts

[0063] Peptides of the type described above are typically made by solid state synthesis. Because solid state synthesis uses trifluoroacetate (TFA) to remove protecting groups or remove peptides from a resin, peptides are typically initially produced as trifluoroacetate salts. The trifluoroacetate can be replaced with another anion by for example, binding the peptide to a solid support, such as a column, washing the column to remove the existing counterion, equilibrating the column with a solution containing the new counterion and then eluting the peptide, e.g., by introducing a hydrophobic solvent such as acetonitrile into the column. Replacement of trifluoroacetate with acetate can be done with an acetate wash as the last step before peptide is eluted in an otherwise conventional solid state synthesis. Replacing trifluoroacetate or acetate with chloride can be done with a wash with ammonium chloride followed by elution. Use of a

hydrophobic support is preferred and preparative reverse phase HPLC is particularly preferred for the ion exchange. Trifluoroacetate can be replaced with chloride directly or can first be replaced by acetate and then the acetate replaced by chloride.

[0064] Counterions, whether trifluoroacetate, acetate or chloride, bind to positively charged atoms on TAT-NR2B9c, particularly the N-terminal amino group and amino side chains arginine and lysine residues. Although practice of the invention, it is not dependent on understanding the exact stoichiometry of peptide to anion in a salt of TAT-NR2B9c, it is believed that up to about 9 counterion molecules are present per molecule of salt.

[0065] Although replacement of one counterion by another takes place efficiently, the purity of the final counterion may be less than 100%. Thus, reference to a chloride salt of TAT-NR2B9c or other active agent means that in a preparation of the salt, chloride is the predominant anion by weight (or moles) over all other anions present in the aggregate in the salt. In other words, chloride constitutes greater than 50% and preferably greater than 75%, 95%, 99%, 99.5% or 99.9% by weight or moles of the all anions present in the salt. In such a salt or formulation prepared from the salt, acetate and trifluoroacetate in combination and individually constitutes less than 50%, 25%, 5%, 5% or 0.1 of the anions in the salt or formulation.

#### IV. Diseases

[0066] The lyophilized formulations are useful in treating a variety of diseases, particularly neurological diseases, and especially diseases mediated in part by excitotoxicity. Such diseases and conditions include stroke, epilepsy, hypoxia, subarachnoid hemorrhage, traumatic injury to the CNS not associated with stroke such as traumatic brain injury and spinal cord injury, other cerebral ischemia, Alzheimer's disease and Parkinson's disease. Other neurological diseases treatable by agents of the invention not known to be associated with excitotoxicity include anxiety and pain.

[0067] A stroke is a condition resulting from impaired blood flow in the CNS regardless of cause. Potential causes include embolism, hemorrhage and thrombosis. Some neuronal cells die immediately as a result of impaired blood flow. These cells release their component molecules including glutamate, which in turn activates NMDA receptors, which raise intracellular calcium levels, and intracellular enzyme levels leading to further neuronal cell death (the excitotoxicity cascade). The death of CNS tissue is referred to as infarction. Infarction Volume (i.e., the volume

of dead neuronal cells resulting from stroke in the brain) can be used as an indicator of the extent of pathological damage resulting from stroke. The symptomatic effect depends both on the volume of an infarction and where in the brain it is located. Disability index can be used as a measure of symptomatic damage, such as the Rankin Stroke Outcome Scale (Rankin, Scott Med J;2:200-15 (1957)) and the Barthel Index. The Rankin Scale is based on assessing directly the global conditions of a patient as follows.

[0068] 0: No symptoms at all

1: No significant disability despite symptoms; able to carry out all usual duties and activities.

2: Slight disability; unable to carry out all previous activities but able to look after own affairs without assistance.

3: Moderate disability requiring some help, but able to walk without assistance

4: Moderate to severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance.

5: Severe disability; bedridden, incontinent, and requiring constant nursing care and attention.

[0069] The Barthel Index is based on a series of questions about the patient's ability to carry out 10 basic activities of daily living resulting in a score between 0 and 100, a lower score indicating more disability (Mahoney et al, Maryland State Medical Journal 14:56-61 (1965)).

[0070] Alternatively stroke severity/outcomes can be measured using the NIH stroke scale, available at world wide web [ninds.nih.gov/doctors/NIH Stroke ScaleJBooklet.pdf](http://ninds.nih.gov/doctors/NIH%20Stroke%20ScaleJBooklet.pdf).

[0071] The scale is based on the ability of a patient to carry out 11 groups of functions that include assessments of the patient's level of consciousness, motor, sensory and language functions.

[0072] An ischemic stroke refers more specifically to a type of stroke that caused by blockage of blood flow to the brain. The underlying condition for this type of blockage is most commonly the development of fatty deposits lining the vessel walls. This condition is called atherosclerosis. These fatty deposits can cause two types of obstruction. Cerebral thrombosis refers to a thrombus (blood clot) that develops at the clogged part of the vessel "Cerebral embolism" refers generally

to a blood clot that forms at another location in the circulatory system, usually the heart and large arteries of the upper chest and neck. A portion of the blood clot then breaks loose, enters the bloodstream and travels through the brain's blood vessels until it reaches vessels too small to let it pass. A second important cause of embolism is an irregular heartbeat, known as arterial fibrillation. It creates conditions in which clots can form in the heart, dislodge and travel to the brain. Additional potential causes of ischemic stroke are hemorrhage, thrombosis, dissection of an artery or vein, a cardiac arrest, shock of any cause including hemorrhage, and iatrogenic causes such as direct surgical injury to brain blood vessels or vessels leading to the brain or cardiac surgery. Ischemic stroke accounts for about 83 percent of all cases of stroke.

[0073] Transient ischemic attacks (TIAs) are minor or warning strokes. In a TIA, conditions indicative of an ischemic stroke are present and the typical stroke warning signs develop. However, the obstruction (blood clot) occurs for a short time and tends to resolve itself through normal mechanisms. Patients undergoing heart surgery are at particular risk of transient cerebral ischemic attack.

[0074] Hemorrhagic stroke accounts for about 17 percent of stroke cases. It results from a weakened vessel that ruptures and bleeds into the surrounding brain. The blood accumulates and compresses the surrounding brain tissue. The two general types of hemorrhagic strokes are intracerebral hemorrhage and subarachnoid hemorrhage. Hemorrhagic stroke result from rupture of a weakened blood vessel ruptures. Potential causes of rupture from a weakened blood vessel include a hypertensive hemorrhage, in which high blood pressure causes a rupture of a blood vessel, or another underlying cause of weakened blood vessels such as a ruptured brain vascular malformation including a brain aneurysm, arteriovenous malformation (AVM) or cavernous malformation. Hemorrhagic strokes can also arise from a hemorrhagic transformation of an ischemic stroke which weakens the blood vessels in the infarct, or a hemorrhage from primary or metastatic tumors in the CNS which contain abnormally weak blood vessels. Hemorrhagic stroke can also arise from iatrogenic causes such as direct surgical injury to a brain blood vessel. An aneurysm is a ballooning of a weakened region of a blood vessel. If left untreated, the aneurysm continues to weaken until it ruptures and bleeds into the brain. An arteriovenous malformation (AVM) is a cluster of abnormally formed blood vessels. A cavernous malformation is a venous abnormality that can cause a hemorrhage from weakened venous structures. Any one of these vessels can rupture, also causing bleeding into the brain. Hemorrhagic stroke can also result from

physical trauma. Hemorrhagic stroke in one part of the brain can lead to ischemic stroke in another through shortage of blood lost in the hemorrhagic stroke.

[0075] One patient class amenable to treatments are patients undergoing a surgical procedure that involves or may involve a blood vessel supplying the brain, or otherwise on the brain or CNS. Some examples are patients undergoing cardiopulmonary bypass, carotid stenting, diagnostic angiography of the brain or coronary arteries of the aortic arch, vascular surgical procedures and neurosurgical procedures. Additional examples of such patients are discussed in section IV above. Patients with a brain aneurysm are particularly suitable. Such patients can be treated by a variety of surgical procedures including clipping the aneurysm to shut off blood, or performing endovascular surgery to block the aneurysm with small coils or introduce a stent into a blood vessel from which an aneurysm emerges, or inserting a microcatheter. Endovascular procedures are less invasive than clipping an aneurysm and are associated with a better patient outcome but the outcome still includes a high incidence of small infarctions. Such patients can be treated with an inhibitor of PSD95 interaction with NMDAR 2B and particularly the agents described above including the peptide YGRKKRRQRRKLSSIESDV (SEQ ID NO:6, also known as Tat-NR2B9c). The timing of administration relative to performing surgery can be as described above for the clinical trial.

[0076] Another class of patients amenable to treatment are patients having a subarachnoid hemorrhage with or without an aneurysm (see US 61/570,264).

#### IV. Effective Regimes of Administration

[0077] After reconstitution, a lyophilized formulation, is administered such that the active agent (e.g., NR2B9c) is administered in an amount, frequency and route of administration effective to cure, reduce or inhibit further deterioration of at least one sign or symptom of a disease in a patient having the disease being treated. A therapeutically effective amount means an amount of active agent sufficient significantly to cure, reduce or inhibit further deterioration of at least one sign or symptom of the disease or condition to be treated in a population of patients (or animal models) suffering from the disease treated with an agent of the invention relative to the damage in a control population of patients (or animal models) suffering from that disease or condition who are not treated with the agent. The amount is also considered therapeutically effective if an individual treated patient achieves an outcome more favorable than the mean outcome in a

control population of comparable patients not treated by methods of the invention. A therapeutically effective regime involves the administration of a therapeutically effective dose at a frequency and route of administration needed to achieve the intended purpose.

[0078] For a patient suffering from stroke or other ischemic condition, the active agent is administered in a regime comprising an amount frequency and route of administration effective to reduce the damaging effects of stroke or other ischemic condition. When the condition requiring treatment is stroke, the outcome can be determined by infarction volume or disability index, and a dosage is considered therapeutically effective if an individual treated patient shows a disability of two or less on the Rankin scale and 75 or more on the Barthel scale, or if a population of treated patients shows a significantly improved (i.e., less disability) distribution of scores on a disability scale than a comparable untreated population, see Lees et al L, N Engl J Med 2006;354:588-600. A single dose of agent is usually sufficient for treatment of stroke.

[0079] The invention also provides methods and formulations for the prophylaxis of a disorder in a subject at risk of that disorder. Usually such a subject has an increased likelihood of developing the disorder (e.g., a condition, illness, disorder or disease) relative to a control population. The control population for instance can comprise one or more individuals selected at random from the general population (e.g., matched by age, gender, race and/or ethnicity) who have not been diagnosed or have a family history of the disorder. A subject can be considered at risk for a disorder if a "risk factor" associated with that disorder is found to be associated with that subject. A risk factor can include any activity, trait, event or property associated with a given disorder, for example, through statistical or epidemiological studies on a population of subjects. A subject can thus be classified as being at risk for a disorder even if studies identifying the underlying risk factors did not include the subject specifically. For example, a subject undergoing heart surgery is at risk of transient cerebral ischemic attack because the frequency of transient cerebral ischemic attack is increased in a population of subjects who have undergone heart surgery as compared to a population of subjects who have not.

[0080] Other common risk factors for stroke include age, family history, gender, prior incidence of stroke, transient ischemic attack or heart attack, high blood pressure, smoking, diabetes, carotid or other artery disease, atrial fibrillation, other heart diseases such as heart disease, heart

failure, dilated cardiomyopathy, heart valve disease and/or congenital heart defects; high blood cholesterol, and diets high in saturated fat, trans fat or cholesterol.

[0081] In prophylaxis, a lyophilized formulation after reconstitution is administered to a patient at risk of a disease but not yet having the disease in an amount, frequency and route sufficient to prevent, delay or inhibit development of at least one sign or symptom of the disease. A prophylactically effective amount means an amount of agent sufficient significantly to prevent, inhibit or delay at least one sign or symptom of the disease in a population of patients (or animal models) at risk of the disease relative treated with the agent compared to a control population of patients (or animal models) at risk of the disease not treated with a chimeric agent of the invention. The amount is also considered prophylactically effective if an individual treated patient achieves an outcome more favorable than the mean outcome in a control population of comparable patients not treated by methods of the invention. A prophylactically effective regime involves the administration of a prophylactically effective dose at a frequency and route of administration needed to achieve the intended purpose. For prophylaxis of stroke in a patient at imminent risk of stroke (e.g., a patient undergoing heart surgery), a single dose of agent is usually sufficient.

[0082] Depending on the agent, administration can be parenteral, intravenous, nasal, oral, subcutaneous, intra-arterial, intracranial, intrathecal, intraperitoneal, topical, intranasal or intramuscular. Intravenous administration is preferred for peptide agents.

[0083] For administration to humans, a preferred dose of active agent (e.g., Tat-NR2B9c) is 2-3mg/kg and more preferably 2.6 mg/kg. Indicated dosages should be understood as including the margin of error inherent in the accuracy with which dosages can be measured in a typical hospital setting. Such amounts are for single dose administration, i.e., one dose per episode of disease.

[0084] Active agents, such as Tat-NR2B9c are preferably delivered by infusion into a blood vessel, more preferably by intravenous infusion. The time of the infusion can affect both side effects (due e.g., to mast cell degranulation and histamine release) and efficacy. In general, for a given dosage level, a shorter infusion time is more likely to lead to histamine release. However, a shorter infusion time also may result in improved efficacy. Although practice of the invention is not dependent on an understanding of mechanism, the latter result can be explained both because

of the delay being significant relative to development of pathology in the patient and because of the delay being significant relative to the plasma half-life of the chimeric agent, as a result of which the chimeric agent does not reach an optimal therapeutic level. For the chimeric agent Tat-NR2B9c, a preferred infusion time providing a balance between these considerations is 5-15 minutes and more preferably 10 min. Indicated times should be understood as including a marking of error of +/- 10%. Infusion times do not include any extra time for a wash out diffusion to wash out any remaining droplets from an initial diffusion that has otherwise proceeded to completion. The infusion times for Tat-NR2B9c can also serve as a guide for other active agents.

**[0085]** Although the invention has been described in detail for purposes of clarity of understanding, certain modifications may be practiced within the scope of the appended claims. All publications, accession numbers, and patent documents cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each were so individually denoted. To the extent more than one sequence is associated with an accession number at different times, the sequences associated with the accession number as of the effective filing date of this application is meant. The effective filing date is the date of the earliest priority application disclosing the accession number in question. Unless otherwise apparent from the context any element, embodiment, step, feature or aspect of the invention can be performed in combination with any other.

## EXAMPLES

**[0086]** Examples 1-7 show that an acetate salt of TAT-NR2B9c can be formulated in lyophilized form with histidine and trehalose. Example 10 shows that the chloride salt of TAT-NR2B9c offers significantly greater stability than the acetate salt in an otherwise identical lyophilized formulation. Example 9 shows that the chloride salt of TAT-NR2B9c formulated in histidine and trehalose also gives improved stability relative to a previously described lyophilized formulation of TAT-NR2B9c from normal saline.

### **Example 1: Demonstration that Standard buffers and excipients do not interfere with the efficacy of TAT-NR2B9c in vivo.**

**[0087]** Five liquid toxicology formulations were compounded targeted at a 20 mg/mL concentration of TAT-NR2B9c. Table 1 includes the vehicle composition, Lot Number, and the

potency, purity and pH at the time of compounding. Approximately 5 mL of each formulation was vialled for testing. Vials were frozen at -20 to simulate transport or liquid storage conditions.

Table 1: composition of TAT-NR2B9c formulations for efficacy testing in vivo

Formulation #	Vehicle Composition	PFek Lot #	Potency <sup>1</sup> (mg/mL)	Purity <sup>2</sup> (% Area of NA-1 peak)	pH <sup>3</sup>
1	50 mM sodium phosphate, 76.9 mM NaCl, pH 7.0	1205-1-17-1	20.5	97.87	6.7
2	50 mM sodium phosphate, 154 mM Mannitol, pH 7.0	1205-1-17-2	20.0	96.34 <sup>2</sup>	6.5
3	50 mM histidine, 154 mM Mannitol, pH 6.5	1205-1-17-3	19.9	98.36	6.4
4	50 mM histidine, 154 mM Trehalose, pH 6.5	1205-1-17-4	20.8	99.16	6.4
5	50 mM histidine, 5% Dextran-40, pH 6.5	1205-1-18-1	19.4	98.81	6.4

<sup>1</sup>Potency and purity were evaluated by RP-HPLC analysis using a TFA method

<sup>2</sup>The purity of formulation #2 is notably lower than the other formulations.

<sup>3</sup>The pH of the phosphate buffered formulations noticeably deviated from the initial buffer pH of 7.0.

[0088] It was noted that phosphate buffered formulation did not maintain pH as well as the histidine buffers did between formulation and testing, indicating that histidine may be a superior buffer for formulation.

[0089] Formulations 1-5 were tested in the 3-PIAL Vessel Occlusions (3PVO) model of stroke in rats. Rats subjected to stroke were given one of the formulations by intravenous administration into the femoral vein, and then the animals were sacrificed 24 hours after the stroke. Brains were harvested, fixed and stained with triphenyltetrazolium chloride (TTC) to visualize the ischemic portions of the brain. All of the formulations tested were able to provide significant neuroprotection in animals relative to the saline-only control (Fig. 1).

## Methods

### *Three pial vessel occlusion model of ischemia*

[0090] Experiments were performed on rats. For permanent three pial vessels occlusion (3PVO) was performed as described previously [Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat. Forder et al., Am J Physiol Heart Circ Physiol.

2005 Apr;288(4):H1989-96]. In brief, 250 g to 350 g rats were anesthetized with a 0.5 ml/kg intramuscular injection of ketamine (100 mg/kg), acepromazine (2 mg/kg), and xylazine (5 mg/kg), supplemented with one-third of the initial dose as required. An anal temperature probe was inserted, and the animal was placed on a heating pad maintained at about 37°C. The skull was exposed via a midline incision and scraped free of tissue. Using a dissecting microscope and a pneumatic dental drill, a 6- to 8-mm cranial window was made over the right somatosensory cortex (2 mm caudal and 5 mm lateral to bregma) by drilling a rectangle through the skull and lifting off the piece of skull while keeping the dura intact. The 3 pial arteriolar middle cerebral artery branches were cauterized around the barrel cortex were selected and electrically cauterized through the dura. After the cauterizations, the scalp was sutured. Each rat was returned to its individual cage under a heating lamp to maintain body temperature until the rat fully recovered. Food and water was supplied. One hour after 3PVO ischemia the rats were injected with NA1 formulations at 3 nmol/g in ~0.45 mL saline based upon rat weight. Doses were administered over 5 minutes.

[0091] Twenty-four hours after surgery, the brain was quickly harvested. Coronal slices (2 mm) were taken through the brain and incubated in 2% triphenyltetrazolium chloride (TTC) (*Sigma-Aldrich* St. Louis MO) for 15 min at 37°C. Images were scanned (CanoScan 4200F Canon) and quantitated.

**Example 2: Determination of TAT-NR2B9c stability in different buffers and at different pH values**

Screening of buffers

[0092] Ten buffers were compounded at 1 mg/mL TAT-NR2B9c for excipient screening. Samples were stored at 25°C/60% relative humidity (RH) and 40°C/75%RH. Samples were tested for stability (purity) at t=0 and t=1 week for purity by RP-HPLC (TFA and MSA methods), and the results are shown in Tables 2 and 3.

[0093] Results indicate improved stability for TAT-NR2B9c in liquid media buffered between pH 6.0 and pH 6.5. Degradation appears to increase outside of this range in either direction. Data generated with the MSA method showed clear degradation patterns that were both pH and buffering species dependent, and provided valuable insight into future formulation development. Results for main peak purity by % HPLC Area using the MSA method are provided in Table 2,

while results for main peak purity by %HPLC Area using the TFA method are provided in Table 3.

**Table 2. % Area of the Main Peak by MSA Method, TAT-NR2B9c**

Sample	t=0	t=1 week 25°C	t=1 week 40°C
His, 6.0	98.5	98.5	98.0
His, 6.5	98.5	98.8	97.3
His, 7.0	98.5	98.4	97.0
Phos, 6.0	98.3	98.2	97.0
Phos, 6.5	98.5	97.9	97.3
Phos, 7.0	98.5	97.9	96.0
Phos, 7.5	98.5	97.8	95.2
Ctr, 5.5	98.5	98.3	94.4
Ctr, 6.0	98.5	98.4	97.4
Ctr, 6.5	98.5	98.7	97.7

**Table 3. % Area of the Main Peak by TFA Method, TAT-NR2B9c**

Sample	t=0	t=1 week 25°C	t=1 week 40°C
His, pH 6.0	99.5	98.8	99.2
His, pH 6.5	98.5	98.4	99.4
His, pH 7.0	99.5	98.3	98.7
Phos, 6.0	99.5	99.8	97.9
Phos, 6.5	99.5	99.8	98.6
Phos, 7.0	99.5	99.8	99.3
Phos, 7.5	99.5	98.8	93.3
Ctr, 5.5	98.5	98.0	95.1
Ctr, 6.0	98.5	99.0	98.2
Ctr, 6.5	98.5	99.5	99.1

[0094] Results indicate that TAT-NR2B9c solution stability is best maintained in pH 6.0 to 6.5 buffered media and the vehicle is still well tolerated for administration by IV. In general, histidine and citrate buffering systems were able to maintain TAT-NR2B9c in an intact form even when kept at accelerated stability conditions of 25°C or 40°C for 1 week.

[0095] There are several factors to consider when selecting a buffering species: the specific degradation patterns that occur in each media, and any data on identified related substances or toxicology concerns may streamline the decision process if specified related substances should be avoided. For the period tested, histidine and citrate buffers between pH 6 and 6.5 showed few degradation products. The histidine buffer itself used in this study contained a contaminant that was present in the histidine buffer in the absence of added TAT-NR2B9c. Therefore,

identification of a supplier of histidine without such a contaminant would make analysis simpler. Table 4 provides a summary of the buffer species from the standpoint of TAT-NR2B9c stability.

**Table 4. Buffering Species Selection**

Species	pH	Pro	Con
Histidine	6.0	Excellent stability, historic use in lyophilization applications, well within buffering range	Chromatographic interference, but chromatography could possibly be improved by new histidine vendor
Citrate	6.0	improved stability, historic use in lyophilization applications, well within buffering range	
Histidine	6.5	improved stability, historic use in lyophilization applications, well within buffering range	Chromatographic interference, but chromatography could possibly be improved by new histidine vendor
Citrate	6.5	Excellent stability, historic use in lyophilization applications, well within buffering range	Target pH of 6.5 may be on the edge of the ideal buffering range for the citrate species
phosphate	6.5	improved stability, historic use of phosphate species in NA-1 formulations	phosphate species has been historically avoided for lyophilization formulations

**Example 3: Determination of TAT-NR2B9c stability in histidine and citrate buffers and at different pH values with varying amounts of sodium chloride.**

[0096] The goal of this study was to demonstrate the effects of sodium chloride (NaCl) on pH and TAT-NR2B9c stability in liquid formulations. Buffer formulations with 1 mg/mL TAT-NR2B9c are listed in Table 5, and results for pH are provided in Table 6. The data show fairly consistent results for the duration of the study. However, notable shifts occurred in citrate with the addition of NaCl, where the buffering capacity was impacted and the pH dropped by ~0.2 units. Selected pH's of 6.0 and 6.5 are on the outside edge of citrate's ideal buffering range (pH 2.5-5.6), so this may cause difficulties with various additives during the compounding process and should be considered when evaluating formulation robustness.

**Table 5: Buffer formulations for examining the effect of salt on pH**

Vehicle #	Buffer	Target pH	NaCl
1	50 mM Citrate	6.0	NA
2	50 mM Citrate	6.0	200 mM
3	50 mM Citrate	6.5	NA
4	50 mM Citrate	6.5	200 mM
5	50 mM Histidine	6.0	NA
6	50 mM Histidine	6.0	200 mM
7	50 mM Histidine	6.5	NA
8	50 mM Histidine	6.5	200 mM

**Table 6: pH Stability of TAT-NR2B9c formulations in under frozen and accelerated temperature conditions**

Vehicle #	Buffer	Target pH	Measured pH	Measured pH	Measured pH	
			t=0 Vehicle	t=0 Vehicle + NaCl	t = 1 week Vehicle	t = 1 week Vehicle + NaCl
1	Ctr	6.0	6.3	6.0	6.1	6.0
		6.5	6.6	6.5	6.6	6.6
3	His	6.0	6.0	5.9	6.2	6.0
		6.5	6.5	6.5	6.6	6.7
5	Ctr + NaCl	6.0	5.8	5.8	5.9	5.8
		6.5	6.3	6.2	6.3	6.3
7	His + NaCl	6.0	6.1	6.0	6.2	6.0
		6.5	6.6	6.6	6.7	6.7

[0097] The results indicate that the addition of 200 mM NaCl to the histidine and citrate buffered TAT-NR2B9c solutions does not significantly affect the pH of the solutions whether stored for a week frozen or at the accelerated temperature of 40°C.

[0098] Next, we examined the stability of TAT-NR2B9c in these formulations when stored 1 week at frozen and accelerated temperatures. Table 7 shows the results of the testing using the RP-HPLC method with an MSA gradient. The data is also presented in Figures 2A and 2B. Figure 2A presents the accelerated stability of formulations sorted from left to right (low to high stability). Figure 2B shows the relative accelerated stability by buffering agent.

**Table 7. Purity (MSA Method), TAT-NR2B9c**

Vehicle	pH 6.0		pH 6.5	
	-20°C	40°C	-20°C	40°C
His	98.1	92.8	98.5	98.9
His + NaCl	98.4	95.0	98.4	97.7
Cit	97.5	96.0	99.0	97.5
Cit + NaCl	98.4	96.7	98.7	98.4

[0099] These results indicate that TAT-NR2B9c solution stability is best maintained at pH 6.5, and the addition of NaCl may offer a slight improvement in stability (Figures 2A and 2B). Due to improved buffering capacity and comparable stability of the histidine buffer, especially when the contaminant migrating with a relative retention time (RRT) of 0.28 is excluded (contaminant area included in the table above, resulting in a lower stability value for the TAT-NR2B9c peak area), the histidine buffering species at pH 6.5 is the best formulation to move into lyophilization studies.

[0100] Vehicles at pH 6.5 are well tolerated for administration by IV.

**Example 4: Selection of bulking agents for TAT-NR2B9c to form a stable lyophilized cake**

[0101] To identify bulking agents that would generate a nice cake upon lyophilization and improve stability, we compounded several 20 mg/mL TAT-NR2B9c solutions in 50 mM histidine buffer, bulking agent and NaCl as outlined in Table 8. To simulate the time and handling temperatures that TAT-NR2B9c formulations may be exposed to during the lyophilization process, these samples were stored at -20°C (control) and 40°C/75%RH (test), and were analyzed after one week of storage for purity by HPLC (MSA method) and pH. Results are

for pH stability are outlined in Table 9, and results for the stability of TAT-NR2B9c in the different liquid formulations are shown in Table 10 and Figure 3.

**Table 8. Bulking Agent Sample Matrix**

Vehicle #	Buffer	Bulking Agent	NaCl
1	50 mM histidine, pH 6.5	120 mM Mannitol	
2	50 mM histidine, pH 6.5	120 mM Mannitol	75 mM
3	50 mM histidine, pH 6.5	120 mM Trehalose	
4	50 mM histidine, pH 6.5	120 mM Trehalose	75 mM
5	50 mM histidine, pH 6.5	5% Dextran-40	
6	50 mM histidine, pH 6.5	5% Dextran-40	75 mM

**Table 9. pH, Bulking Agent Samples**

Vehicle	Target pH	pH, -20°C	pH, 40°C
Mannitol	6.5	6.5	6.5
Mannitol + NaCl	8.5	8.5	8.5
Trehalose	6.5	6.5	6.4
Trehalose + NaCl	8.5	8.5	8.4
Dextran-40	6.5	6.5	6.3
Dextran-40 + NaCl	6.5	6.5	6.4

**Table 10. Purity by % Area of TAT-NR2B9c Peak, MSA Method**

Vehicle #	Vehicle	% Area of TA-1 Peak	
		-20°C	40°C
1	Mannitol	99.3	98.5
2	Mannitol + NaCl	99.4	98.6
3	Trehalose	99.1	98.5
4	Trehalose + NaCl	99.3	98.3
5	Dextran-40	99.2	97.8
6	Dextran-40 + NaCl	99.0	97.7

*Results of bulking agent liquid formulations on TAT-NR2B9c stability*

[00102] Mannitol, Trehalose and Dextran-40 maintain the pH at 6.5 well (Table 9) and there is approximately a 1% decrease in purity (Table 10) over 1 week as a liquid formulation when stored at high temperature. In terms of the chemical stability of the TAT-NR2B9c lyophilization fill solution, mannitol and trehalose are preferred bulking agents as they confer better stability to TAT-NR2B9c than the dextran-40 solutions (Figure 3).

**Example 5: Thermal analysis of bulking agents to facilitate design of lyophilization cycles**

[00103] As part of the lyophilization cycle development for TAT-NR2B9c lyophilized drug product, proposed fill solutions from the bulking agent sample matrix (Table 8) were evaluated by Differential Scanning Calorimetry (DSC) for thermal characteristics including glass transition (T<sub>g</sub>) in the formulation. Results are listed in Table 11 and DSC traces are included in Figures 4A-6B.

**Table 11. Glass Transitions of TAT-NR2B9c Lyophilization Fill Solutions**

Vehicle	T <sub>g</sub>
50 mM histidine, pH 6.5, 120 mM Mannitol	-37.25°C
50 mM histidine, pH 6.5, 120 mM Mannitol, 75 mM NaCl	-42.51°C
50 mM histidine, pH 6.5, 120 mM Trehalose	-28.25°C
50 mM histidine, pH 6.5, 120 mM Trehalose, 75 mM NaCl	-35.74°C
50 mM histidine, pH 6.5, 5% Dextran-40	-17.09°C
50 mM histidine, pH 6.5, 5% Dextran-40, 75 mM NaCl	-22.49°C

[00104] At a TAT-NR2B9c concentration of 20 mg/mL, tested TAT-NR2B9c formulations showed a thermal profile characterized by a broad melting event with onset at a low temperature. This extended melt masked the crystallization event typically seen in mannitol formulations, and may indicate that a robust freeze drying cycle must be performed where the product never exceeds the glass transition temperature. In this case, based on the observed glass transitions of the TAT-NR2B9c drug product fill solution, the use of mannitol as a bulking agent would require a primary drying temperature lower than -40°C, the typical limit of feasibility for a scalable cycle. In terms of thermal profiles, Trehalose and Dextran-40 are superior for use as a bulking agent. However, given that the stability of TAT-NR2B9c in the liquid formulations containing trehalose was superior to those containing Dextran, trehalose would be the preferred bulking agent of those tested.

[00105] Due to the relatively low T<sub>g</sub> temperatures that would likely require a longer lyophilization cycle to dry, we looked at a wider range of standard bulking agents and looked to reduce the fill volume into the container closure system so that there would be a reduced volume of liquid to lyophilize. In an effort to decrease the fill volume and maintain 270 mg/vial, a solubility study of TAT-NR2B9c in Histidine, pH 6.5 and in Histidine + Trehalose, pH 6.5 was performed. Samples were visually analyzed at 35, 50, 75 and 100 mg/mL. All solutions were clear at t=0 and t=24 hours. Based on this data, we could use fill volume lower than 3 mL, which

using a 90 mg/mL TAT-NR2B9c formulation would give provide 270 mg in a target vial. A wide range of quantities may be required in a vial, but 270 mg would provide a 2.6 mg/kg dose for a 100 kg patient. Assuming the target reconstitution concentration for patient administration is still 20 mg/mL (but can be from 1 mg/ml to 100 mg/ml), then a 20-mL lyophilization vial containing 270 mg of TAT-NR2B9c can be used with a reconstitution volume of 13.5 mL. Therefore, optimal volumes of liquid for lyophilization of TAT-NR2B9c in the vial would be between 2.5mL and 10 mL.

[00106] A wider range of bulking agents were tested prior to advancing into lyophilization development, and the Tg's are shown in Table 12. The 100 mg/mL TAT-NR2B9c in histidine, pH 6.5 was also evaluated by DSC and the data is included in Table 12.

**Table 12. DSC Data, Formulations**

Formulation	Bulking Agent	Vehicle		DP Fill Solution
		T <sub>g</sub>	Temp of Crystallization	
1	Sorbitol	-41.03°C		
2	Dextrose	-38.78°C		
3	Sucrose	-31.09°C		
4	Mannitol	-37.98°C	-22.91°C	-35.49°C
5	Trehalose	-29.93°C		-28.25°C
6	Lactose	-27.83°C		
7	75:25 Trehalose:Dextran-40	-25.07°C		-25.07°C
8	50:50 Trehalose:Dextran-40	-22.80°C		-22.80°C
9	25:75 Trehalose:Dextran-40	-18.55°C		-18.55°C
10	Dextran-40			-17.09°C
11	100 mg/ml NA-1 in Histidine, pH 6.5			-21.67°C

[00107] Based on the DSC data in Table 12, there are several formulation options for both active and placebo drug products. In general, formulations 5 and 11 are the most promising for the active product with respect to the Tg. Any bulking agent may be suitable for use in a placebo product, but Formulation 4 (Mannitol) will have the shortest cycle length if annealed, and may be the most desirable should the appearance match the active.

[00108] As we determine an optimal active formulation, it is important to consider solution stability, lyophilization cycle robustness, and chemical stability. Formulation 5 from Table 12 (Trehalose) demonstrated good solution stability and lyophile chemical stability at accelerated conditions (data shown subsequently), but requires a longer lyophilization cycle at a fill

configuration of 13.5 mL. This longer cycle length may not be ideal for commercial manufacture in the future, where a shorter cycle is desirable. Formulation 11 from Table 12 (without a bulking agent, at 100 mg/mL TAT-NR2B9c) has a higher glass transition temperature than Formulation 5, allowing for a warmer, shorter cycle. In addition, a decreased fill volume will significantly shorten the run time as there will be less ice to sublimate from each vial.

**Example 6: Stability of TAT-NR2B9c with varying bulking agents, scales and lyophilization conditions**

*Bulking Agent Accelerated Stability*

[00109] A small batch of TAT-NR2B9c drug product was lyophilized to evaluate solid state stability after 1 week at 25°C, 40°C, and 60°C. TAT-NR2B9c was compounded at an active concentration of 20 mg/mL in three different vehicles. Samples were evaluated for appearance, reconstitution, pH, amount and purity by HPLC (MSA method) at t=0 and t=1 week. Water content was evaluated at t=0 only.

[00110] All TAT-NR2B9c drug products appeared as white, lyophilized cakes and reconstituted in less than 10 seconds at t=0 and t=1 week.

[00111] The drug product vehicles are described in Table 13 and are listed with the respective glass transition temperature and water content results. The pH, TAT-NR2B9c amount and TAT-NR2B9c purity results are described in Tables 14-16.

**Table 13. Bulking Agent Sample Matrix: T<sub>g</sub> and % Water Content**

Vehicle #	Vehicle	T <sub>g</sub>	t=0 % Water Content
1	50 mM His, pH 6.5+ 130 mM Trehalose	-29.93°C -38.25°C w/NA-1	0.28%
2	50 mM His, pH 6.5+ 5% Dextran-40	-23.60°C	0.05%
3	50 mM His, pH 6.5 + 1:1 130 mM Trehalose; 5% Dextran-40	-17.09°C w/NA-1	0.10%

**Table 14. pH, Bulking Agent Lyo Small Scale #1**

Bulking Agent	Theoretical pH	Measured pH			
		t=0	t=1wk 25°C	t=1wk 40°C	t=1wk 60°C
Trehalose	6.5	6.4	6.4	5.4	6.4
Dextran-40	6.5	6.4	6.3	6.3	6.3
1:1 Trehalose:Dextran	6.5	6.4	6.3	6.4	6.4

**Table 15. Amount (mg/vial), Bulking Agent Lyo Small Scale #1**

Bulking Agent	t=0	t=1 week 25°C	t=1 week 40°C	t=1 week 60°C
Trehalose	20.6	20.3	20.7	20.7
Dextran-40	19.4	19.8	19.5	19.1
1:1 Trehalose:Dextran-40	20.3	20.8	20.2	20.2

**Table 16. Purity (% Area by HPLC), Bulking Agent Lyo Small Scale #1**

Bulking Agent	t=0	t=1 week 25°C	t=1 week 40°C	t=1 week 60°C
Trehalose	98.8	99.8	99.8	98.4
Dextran-40	98.9	98.9	98.6	96.5
1:1 Trehalose:Dextran-40	98.9	99.8	98.6	97.5

[00112] All three bulking agents, Trehalose, Dextran-40 and Trehalose:Dextran-40, maintain the pH at 6.5 (Table 14) and there is a range of 0.5-2.5% decrease in purity at 60°C after 1 week (Table 15). Both drug products containing dextran-40 and stored at 60°C showed growth in related substances at a retention time (RT) ~6.0. These related substances were not present in the trehalose samples, suggesting that trehalose has a stabilizing effect in the lyophilized drug product and dextran-40 can cause a specific degradation product.

[00113] The inclusion of dextran-40 in the bulking agent allows for a warmer primary drying temperature, but dextran-40 as a bulking agent demonstrated the poorest stability. The combination of trehalose and dextran-40 (1:1) results in a glass transition temperature that is approximately 10°C warmer than trehalose alone. However, it appears that the 60°C stability is intermediate to the trehalose and dextran alone samples, so that trehalose is a preferred bulking

agent.

*Lyophilized TAT-NR2B9c Formulation Development: Small Scale Experiment #2*

[00114] A small batch of TAT-NR2B9c drug product was lyophilized to evaluate setting the shelf temperature at 5°C during primary drying. TAT-NR2B9c was compounded at an active concentration of 27 mg/mL in 50 mM Histidine, pH 6.5 and 120 mM Trehalose. The cycle parameters are outlined in Table 17. Four 20-mL glass lyophilization vials were filled with 10 mL. Two vials were probed with temperature probes.

**Table 17. Small Scale 2, TAT-NR2B9c Formulation Development**

Function	Temperature (°C)	Hold/Rate	Rate (°C/minute)	Time (minutes)	Pressure (mTorr)
Load	5	Hold	~	0	Ambient
Equilibration	5	Hold	~	120	Ambient
Freeze	-40	Rate	0.5	90	Ambient
Freeze	-40	Hold	~	240	Ambient
Primary Drying <sup>1</sup>	5	Rate	0.25	180	225
Primary Drying <sup>1</sup>	5	Hold	~	2050	50
Secondary Drying	25	Rate	0.1	200	50
Secondary Drying	25	Hold	~	1440	50
Stopper	20	Hold	~	~	Nitrogen/Ambient
Unload	20	Hold	~	~	Ambient

<sup>1</sup>Primary drying temperature based on large vial size and fill volume, not directly related to glass transition temperature.

[00115] Due to the large fill volume, it is necessary to set the shelf temperature considerably warmer than the glass transition temperature in order to compensate for evaporative cooling. The solution temperature during primary drying was at -29°C, which is near the glass transition temperature of -28°C from the DSC thermal analysis.

*90 mg/mL TAT-NR2B9c Lyophile Accelerated Stability (Small Scale 3)*

[00116] Prior to compounding the small scale 3 fill solution, a 90 mg/mL TAT-NR2B9c in buffer (50 mM Histidine, pH 6.5) was evaluated for pH. The pH of the solution was 6.04. It was determined that with the increased concentration of TAT-NR2B9c, the buffering strength also needed to increase. Solutions were prepared at 150mM, 100 mM, 75 mM, and water and evaluated for pH. The pHs are listed in Table 18. Small scale 3 was compounded in a 100 mM Histidine buffer at pH 6.5, and the pH was re-adjusted to 6.5 after addition of TAT-NR2B9c.

**Table 18. pH, 90 mg/mL TAT-NR2B9c in Histidine Buffers, pH 6.5**

Buffer	pH
Water	5.39
50mM	6.04
75mM	6.04
100mM	6.29
150mM	6.14

[00117] A small batch of TAT-NR2B9c drug product was lyophilized to evaluate solid state stability after 1 week storage at 25°C and 60°C. Two 90 mg/mL TAT-NR2B9c formulations were compounded (buffer and buffer with trehalose). Samples were evaluated for appearance, reconstitution, water content and purity by HPLC (MSA method) at t=0 and t=1 week.

[00118] All TAT-NR2B9c drug products appeared as white, lyophilized cakes. Some cakes were cracked. Placebo formulations were visually similar to the active formulations.

[00119] Reconstitution time was approximately 1.5 minutes compared to less than 10 seconds in the previous formulations. The increased reconstitution time is most likely due to the increased concentrations of TAT-NR2B9c and histidine. Further tests showed good stability of TAT-NR2B9c with histidine buffer concentrations of 50 and 75 mM, with shortened resuspension times. Also, due to the 2-mL vial size used for this study, only 1 mL of water was added to the lyophile. The actual reconstitution volume is 4.5 mL in this small scale configuration. The reconstitution time will most likely improve when a larger volume of diluent is used.

[00120] Vials were placed on stability at 25°C and 60°C and tested after 1 week of storage.

[00121] Based on the visual appearance data, the trehalose sample gave a more elegant cake. The lyophilization cycle was run conservatively over 5 days, with a primary drying temperature of -32°. Based on the temperature probe data, the cycle can be shortened, demonstrating that with the higher concentration and lower fill volume the optimized cycle will be shorter.

[00122] Purity results are outlined in Table 19.

**Table 19. Purity (%Area by HPLC), Small Scale 3**

Formulation	Composition	Fill Solution	t=0	t=1 week, 25°C/60°C RH	t=1 week, 60°C
1	100 mM His, pH 6.5	99.2	99.3	99.3	97.8
2	100 mM His, pH 6.5 + 120 mM Trehalose	99.2	99.3	99.2	98.7

[00123] Based on this accelerated stability data, trehalose demonstrates a stabilizing effect on the TAT-NR2B9c formulation which improves the chemical stability of the lyophile. It is surprising that trehalose is able to confer this stabilizing effect while other standard bulking agents such as dextran and mannitol used for other peptides do not.

[00124] The reduced fill volume minimizes the competing evaporative cooling of the surrounding vials and minimizes the resistance to the sublimating water.

*Lyophilization Cycle Development – Small Scale 4 (Placebo and Active)*

[00125] Small scale 4 of the lyophilization cycle development was initiated to test the cake appearance and lyophilization conditions for a 3 mL fill. Samples tested were 100 mM His, pH 6.5 with 120 mM Trehalose and 90 mg/kg TAT-NR2B9c or an identical sample removing the Trehalose. A conservative, 4 day cycle was ran as described in Table 20. Placebo and active vials were included with a fill configuration of 3 mL into a 20-mL glass lyophilization vial instead of the small vials used for the previous experiments. An active temperature probe was used to confirm temperature during the lyophilization cycle. The resulting active vials is shown in Figure 7A.

**Table 20. Lyophilization Parameters for Small Scale 4**

Function	Temperature (°C)	Hold/Rate	Rate (°C/minute)	Time (minutes)	Pressure (mTorr)
Load	5	Hold	-	0	Ambient
Equilibration	5	Hold	-	120	Ambient
Freeze	-30	Rate	0.5	90	Ambient
Freeze	-40	Hold	-	320	Ambient
Primary Drying	-30	Rate	0.25	48	235
Primary Drying	-30	Hold	-	3400	50
Secondary Drying	25	Rate	0.1	550	50
Secondary Drying	25	Hold	-	1440	50
Stopper	20	Hold	-	-	Nitrogen/Ambient
Unload	20	Hold	-	-	Ambient

[00126] Formulation at 90 mg/ml in a 20 mL vial formed an elegant cake on a 4 day cycle, and temperature probe data suggested that the cycle could be shortened to 3 days.

[00127] Water content for the placebo and active was 0.01% and 0.00%.

*Lyophilization Cycle Development – Small Scale 5 (Placebo and Active)*

[00128] Small Scale 5 was performed to look at developing a matching placebo vial for clinical trials and to look at resuspension times for formulations at a potential commercial scale (270 mg/vial). 10 placebo formulations and 1 active formulation were evaluated for appearance and reconstitution time. The active cakes were elegant, white cakes with minor shrinkage resulting in a crack around the surface of the vial wall. The placebo cakes were white with more cracks in cakes containing increasing amounts of trehalose.

[00129] Vials were reconstituted with 13.5 mL of water. The time to dissolve is listed in Table 21. The active lyophile re-suspended immediately, but was cloudy for 17.6 sec before becoming a clear, colorless solution. All placebos were a clear, colorless solution.

**Table 21. Reconstitution of Placebo and Active (SS5)**

Formulations				Reconstitution Time (min)	
Placebo Formulation #	Trehalose, mM	Histidine, mM	Total, mg/vial	Vial #1	Vial #2
1 (Control)	120	100	170	< 10 sec	< 10 sec
2	200	100	252	< 10 sec	< 10 sec
3	300	100	356	< 10 sec	< 10 sec
4	400	100	457	< 10 sec	< 10 sec
5	500	100	560	< 10 sec	< 10 sec
6	120	20	133	< 10 sec	< 10 sec
7	200	20	213	< 10 sec	< 10 sec
8	300	20	317	< 10 sec	< 10 sec
9	400	20	420	< 10 sec	< 10 sec
10	500	20	523	< 10 sec	< 10 sec
Active Formulation #	Trehalose, mM	Histidine, mM	NA-1, mg	Vial #1	Vial #2
1 (Control)	120	100	90	17.6 sec	NA

[00130] Based on the stability, resuspension times, and lyophilization times, a preferred commercial formulation for TAT-NR2B9c, prelyophilization, would be 20-100 mM Histidine, 120 mM Trehalose pH 6.5. Trehalose concentrations can be increased without a loss of stability or cake elegance but resuspension times.

*Examination of increased Trehalose in cake formation and placebo matching by visual appearance and resuspension time.*

[00131] To better match a placebo, varying concentrations of Trehalose were tested with and without TAT-NR2B9c, and at either 3 or 5 mL fill volumes.

[00132] First, the active formulations and the placebo formulations will be summarized. Then the lead visual matches for the 3-mL fill and the 5-mL fill will be highlighted. Analytical samples (fill solution and one potency sample) are currently being analyzed. Tables 22 and 23 show a subset of the formulations tested.

**Table 22. Active Formulations**

Formulation	Fill Volume	Composition
1	3-mL	270 mg/vial in 120 mM Trehalose + 100 mM Histidine, pH 6.5
2	3-mL	270 mg/vial in 500 mM Trehalose + 20 mM Histidine, pH 6.5
3	5-mL	270 mg/vial in 120 mM Trehalose + 50 mM Histidine, pH 6.5

Figure 7B shows the appearance of the active formulations listed above.

**Table 23. Placebo Formulations**

Placebo Formulations	Active Formulations (~270 mg/vial)
500 mM Trehalose + 20 mM Histidine (n=7)	500 mM Trehalose + 20 mM Histidine (n=2)
400 mM Trehalose + 20 mM Histidine (n=3)	400 mM Trehalose + 20 mM Histidine (n=1)
300 mM Trehalose + 20 mM Histidine (n=3)	300 mM Trehalose + 20 mM Histidine (n=1)

Table 24 shows the lyophilization cycle conditions for the above samples

**Table 24. Cycle Parameters**

Function	Temperature (°C)	Hold/Rate	Rate (°C/minute)	Time (minutes)	Pressure (mTorr)
Load	5	Hold	~	0	Ambient
Equilibration	5	Hold	~	120	Ambient
Freeze	-40	Rate	0.25	180	Ambient
Freeze	-40	Hold	~	120	Ambient
Anneal	-27	Rate	0.25	52	Ambient
Anneal	-27	Hold	~	120	Ambient
Freeze	-40	Rate	0.25	52	Ambient
Freeze	-40	Hold	~	120	Ambient
Primary Drying	-30	Rate	0.25	40	325
Primary Drying	-30	Hold	~	4406	50
Secondary Drying	25	Rate	0.1	650	50
Secondary Drying	25	Hold	~	1440	50
Stopper	20	Hold	~	~	Nitrogen/Ambient
Unload	20	Hold	~	~	Ambient

**Table 25. Summary of Lead Matches**

Sample Name	Color & Texture (Sheen or matte)	Topography: Ex. skin, bumps, cracks, peaks, cavities	Structure: Dense or porous	Shattering	Fractility	Reconstitution Time
558 - 3 ml 30s						
Active #2 200 mM Trehalose 20 mM Histidine	off white matte	thin cracks	dense	minimal		3 min 30 sec
Passive #2 200 mM Trehalose 20 mM Histidine	off white matte	cracked	dense	minimal	see photo	1 min
557 - 3 ml 30s						
Active 200 mM Trehalose 20 mM Histidine	off white matte with tiny specks	cracked pocketed bottom	semi-dense, layered	yes, base of cage	NT	1 min
Passive 200 mM Trehalose 20 mM Histidine	off white matte with tiny specks	cracked pocketed bottom	semi-dense, more porous than active	minimal		30 sec unaccelerated: 30 sec

NT = not tested

**Example 7: Stability of lyophilized 270 mg TAT-NR2B9c in 20 mM Histidine buffer pH 6.5 and 120 mM trehalose**

*Preparation of the lyophilized drug product*

[00133] A small batch of TAT-NR2B9c drug product was formulated at 90 mg/mL in 20 mM Histidine pH 6.5 and 120 mM trehalose and lyophilized to evaluate solid state stability after 4 weeks at -20°C, 40°C, and 60°C. Table 25 shows the lyophilization conditions.

**Table 25: Lyophilization cycle conditions for Example 7**

Function	Temperature (°C)	Hold/Rate	Rate (°C/minute)	Time (minutes)	Pressure (mTorr)
Load	5	Hold	—	0	Ambient
Equilibration	5	Hold	—	120	Ambient
Freeze	-40	Rate	0.5	90	Ambient
Freeze	-40	Hold	—	120	Ambient
Primary Drying	-28	Rate	0.25	48	225
Primary Drying	-28	Hold	—	3432	50
Secondary Drying	-25	Rate	0.1	530	50
Secondary Drying	-25	Hold	—	1480	50
Stopper	20	Hold	—	—	Nitrogen/Ambient
Unload	20	Hold	—	—	Ambient

**[00134]** Samples were stored in constant temperature ovens with and the purity, potency, and reconstitution time in 13.2 mL (for 13.5 final volume) were assessed at 0, 1, 2 and 4 weeks. The data for each storage temperature and time is presented in Tables 26A-C.

**Table 26A: Stability at -20°C**

Parameter	t=0		t=4 weeks	
	Appearance	Reconstitution Time	Appearance	Reconstitution Time
Appearance	Dense white cake	~60 sec	Dense white cake	~60 sec
pH	6.32	—	TBD	—
Water Content	0.02%	—	NT	—
% Label Claim, TFA Method	99.0%	—	101.3%	—
Total Purity, MSA Method (% Area)	99.2%	—	99.2%	—
Individual Impurities	RRT	% Area	RRT	% Area
	0.59	0.02%	0.59	0.03%
	ND	ND	0.95	0.01%
	0.37	0.26%	0.98	0.21%
	1.04	0.26%	1.05	0.32%
	1.07	0.09%	1.09	0.04%
	1.10	0.13%	1.11	0.12%
	ND	ND	1.14	0.03%
	1.15	0.02%	1.16	0.02%
	Deamidated NAs, SCX Method (% Area)		<0.05%	

**Table 26B: Stability at 40°C**

Parameter	t=0		t=3 weeks		t=3 months		t=8 weeks	
Appearance	Dense white cake							
Reconstitution Time <sup>a</sup>	~90 sec		~90 sec		~90 sec		~90 sec	
pH	8.32		8.33		8.21		7.92	
Water Content	5.03%		5.07%		5.07%		5.07%	
% Labeled Cages, TGA Method	99.0%		97.0%		100.0%		100.0%	
Total Impurity, MSA Method (8 weeks)	0.09%		0.13%		0.09%		0.09%	
	8.67	N.D.	8.67	N.D.	8.67	N.D.	8.67	N.D.
	0.55	0.02%	0.55	0.02%	0.55	0.02%	0.55	0.02%
	0.37	0.36%	0.37	0.26%	0.37	0.05%	0.37	0.05%
	1.08	0.26%	1.08	0.25%	1.08	0.23%	1.08	0.23%
	1.07	0.09%	1.07	0.13%	1.07	0.33%	1.07	0.33%
	0.02	N.D.	0.02	N.D.	0.02	N.D.	0.02	N.D.
	0.35	0.13%	1.15	0.33%	1.10	0.33%	1.10	0.33%
	0.02	N.D.	0.53	0.09%	1.12	0.36%	1.12	0.36%
	1.25	0.02%	3.15	0.02%	2.15	0.02%	1.15	N.D.
	0.02	N.D.	0.02	N.D.	0.02	0.02%	0.02	0.02%
	1.35	0.03%	3.28	0.03%	3.25	0.03%	1.28	0.03%
	1.28	0.07%	3.29	0.03%	3.35	0.08%	1.35	0.07%
Unrecovered NDA, FDX Method (8 weeks)	0.05%		N.D.		N.D.		0.05%	

**Table 26C: Stability at 60°C**

Parameter	t=0		t=3 weeks		t=3 months		t=8 weeks	
Appearance	Dense white cake							
Reconstitution Time <sup>a</sup>	~90 sec		~90 sec		~90 sec		~90 sec	
pH	8.32		8.43		8.38		8.63	
Water Content	5.03%		N.D.		N.D.		N.D.	
% Labeled Cages, TGA Method	99.0%		97.0%		100.0%		102.0%	
Total Impurity, MSA Method (8 weeks)	0.09%		0.09%		0.09%		0.09%	
	8.67	N.D.	8.67	N.D.	8.67	N.D.	8.67	N.D.
	0.55	0.55	0.55	0.55	0.55	0.55	0.55	0.55
	0.37	0.32%	0.35	0.32%	0.35	0.32%	0.35	0.32%
	1.08	N.D.	0.92	N.D.	0.92	0.22%	0.92	0.22%
	1.07	0.02%	3.15	0.02%	2.15	0.02%	1.15	0.02%
	0.02	N.D.	0.53	0.09%	1.12	0.36%	1.12	0.36%
	1.25	0.02%	3.15	0.02%	2.15	0.02%	1.15	N.D.
	0.02	N.D.	0.02	N.D.	0.02	0.02%	0.02	0.02%
	1.35	0.03%	3.28	0.03%	3.25	0.03%	1.28	0.03%
	1.28	0.07%	3.29	0.03%	3.35	0.08%	1.35	0.07%
Unrecovered NDA, FDX Method (8 weeks)	0.05%		N.D.		N.D.		0.05%	

<sup>a</sup>less to resolution around main peak.

[00135] This formulation of TAT-NR2B9c is stable at -20°C. For storage temperatures of 40°C and 60°C, potential impurities with relative retention times (RRT) of 1.07, 1.1 and 1.29 increased slowly using the MSA HPLC assay, with the largest growth appearing at 1.07 RRT. For the 40°C storage temperature, the impurity increases from 0.09% to 0.27% over 1 month, and for the 60°C storage temperature the impurity increases from 0.09% to 0.59%. No impurity was observed at -20°C. Impurities interpolated using the Arrhenius equation are less than 0.5% after 16 months at 25°C or 123 months at 5°C, and less than 2% for >60 months at room temperature and many years at 5°C. Thus, this and related formulations are suitable for room temperature storage of lyophilized drug product.

[00136] This degradation study was allowed to proceed another month to confirm that the

degradation products observed at 60°C were also apparent at 40°C. These three impurities did seem to occur at the lower temperature, indicating that they are likely to be degradation products that are not specific to highly elevated temperatures. The identities of these species were determined by LC/MS/MS studies and found to all comprise acetylation of the full length TAT-NR2B9c compound. These acetylation events occurred both at the N-terminus of the peptide and on lysine side chains. Therefore, the stability of TAT-NR2B9c could be increased by either adding a scavenger or other excipients to reduce acetylation of TAT-NR2B9c in the lyophilized state or by reducing or removing the acetate so that there is a reduced chance of acetylation.

#### *Overall conclusions*

[00137] Based on the stability, resuspension times, and lyophilization times, a preferred commercial formulation for TAT-NR2B9c is 20-100 mM Histidine, 120 mM Trehalose pH 6.5. Trehalose concentrations can be increased without a loss of stability or cake elegance but resuspension times increase with increased trehalose concentration.

#### **Example 8: Development and Stability of a Chloride salt of TAT-NR2B9c (TAT-NR2B9c-Cl)**

##### *Preparation of the lyophilized drug product*

[00138] Due to the instability of the previously developed saline formulations of TAT-NR2B9c, and the observation that acetylation of the acetate salt of TAT-NR2B9c can occur in lyophilized formulations, the acetate salt was exchanged to a chloride salt. This was done by preparative RP-HPLC using ammonium chloride. The goal of this method is to identify a novel composition of matter and a novel formulation that will allow improved stability for TAT-NR2B9c, preferably with improved stability at both room temperature and 37°C. Because TAT-NR2B9c is effective when administered to potential victims of stroke and other neurological disorders, and there is a high value to early treatment of these disorders, a formulation that is stable outside of hospital conditions would be valuable in helping the millions of people affected by these disorders every year. For example, such a drug could be stored in ambulances, or small clinics, doctor's offices or even be available to individuals, and provided to subjects having neurological disorders such as stroke or other diseases amenable to neuroprotective agents much earlier than they might be administered if they had to travel to a hospital for treatment.

General Process Protocol:

Buffer A: Water  
 Buffer B: Acetonitrile  
 Column: Daisogel ODS C-18 (1Kg), 120 Å, 15 µm, 10 cm (Bed Volume: ~1L)  
 Flow Rate: 250 mL/min.  
 Wavelength: 230 nm  
 Gradient: Kick out with 20% B

- (1) Column was washed with 2 Bed Volume (BV) 80% CH<sub>3</sub>OH
- (2) Passed 2 BV 0.025% HCl in water or 0.1% TFA in water, which was superior
- (3) Loaded sample: 30g TAT-NR2B9c acetate (PPL-NA11301) was dissolved in 1.5L USP water (20g/L) under which conditions, TAT-NR2B9c binds to the column;
- (4) Rinsed with 200 mL USP water (also loaded to column) removing the existing acetate counterion
- (5) Passed 3 BV 0.1M Ammonium Chloride (NH<sub>4</sub>Cl) to supply new chloride counterion;
- (6) Passed 2 BV 2%
- (7) Passed 20% B (acetonitrile) to elute the product
- (8) Collected fractions when the product peak eluted
- (9) Fractions were analyzed by Analytical HPLC
- (10) Column was back washed with 3 BV 80% CH<sub>3</sub>OH

Analytical HPLC System:

YMC ODS-A C18 Column, 5µm, 120Å; Flow rate: 1.5 mL/min.; Wavelength: 210 nm;  
 Temperature: 50°C; Gradient: 20% to 35% B in 15 min.; Buffer A = 0.1M NaClO<sub>4</sub> pH 3.1,  
 Buffer B = 100% ACN

Synthetic Results and Discussions:

**[00139]** Two main pools collected from the runs were mixed and lyophilized (~5L). 23.4 g of the final product was collected, with the purity 99.01%. The residual acetate was less than 1%. Standard refinements of the protocol should be able to increase the yield from 78% to >95%. This procedure can similarly be used to exchange a TFA salt of TAT-NR2B9c to a chloride salt, as TFA salt will bind the column in step 3 similarly.

*Formulation of a lyophilized form of TAT-NR2B9c-Cl and stability testing*

**[00140]** TAT-NR2B9c-Cl was compounded in 20 mM histidine and 120 mM trehalose, pH 6.5, for direct comparison to a previous preferred lyophilized formulation under the same

lyophilization conditions at 270 mg/vial (active weight). The stability of this formulation was also compared to the previously disclosed formulation of TAT-NR2B9c-Ac resuspended in saline and lyophilized. For the latter, a small batch of TAT-NR2B9c-acetate drug product was formulated at 90 mg/mL in saline (no other excipients) and lyophilized at 270 mg/vial. Stability of the formulations in the lyophilized state was evaluated after 4 weeks at -20°C (control), 40°C and 60°C.

**Table 27: Stability of TAT-NR2B9c-Cl (20 mM histidine, 120 mM trehalose) versus TAT-NR2B9c-Ac (saline)**

NA-1 Chloride salt stability data			NA-1-Ac SALINE stability data		
0.898		0.11	0.898		0.11
0.95			0.95		0.09
0.97		0.07	0.97		0.06
0.98			0.98		0.06
0.99	0.17	0.29	0.18	0.23	0.19
1	97.78	96.64	1	97.93	97.42
1.02	1.22	1.36	1.02	1.22	1.37
1.03	0.11	0.16	1.03	0.1	0.12
1.05	0.08	0.07	1.05	0.08	0.01
1.06			1.06		0.1
1.07	0.32	0.24	1.07	0.2	0.28
1.08			1.08		0.1
1.09		0.06	1.09		0.07
1.1		0.11	1.1		0.12
1.11	0.18	0.09	1.11	0.05	0.06
1.12		0.11	1.12	0.17	0.17
1.13		0.06	1.13	0.05	0.02
1.14		0.09	1.14	0.06	
1.15			1.15		
1.16			1.16		
1.17			1.17		
1.18			1.18		
1.19			1.19		
1.20			1.20		
1.21			1.21		
1.22			1.22		
1.23			1.23		
1.24			1.24		
1.25			1.25		
1.26			1.26		
1.27			1.27		
1.28			1.28		
1.29			1.29		
1.30			1.30		
0.94		0.07	0.94		0.05
0.98	0.11	0.11	0.98	0.06	0.06
1	99.3	99.14	1	99.13	98.89
1.02			1.02		
1.03	0.37	0.31	1.03	0.41	0.32
1.04	0.07	0.06	1.04	0.08	0.08
1.05	0.35	0.26	1.05	0.23	0.21
1.07		0.12	1.07	0.08	0.21
1.08			1.08		
1.1		0.07	1.1		0.09
1.12			1.12		0.07
1.14			1.14		0.1
1.15			1.15		0.06
1.16			1.16		
1.17			1.17		
1.18			1.18		
1.19			1.19		
1.20			1.20		
1.21			1.21		
1.22			1.22		
1.23			1.23		
1.24			1.24		
1.25			1.25		
1.26			1.26		
1.27			1.27		
1.28			1.28		
1.29			1.29		
1.30			1.30		

**Table 28: Stability of TAT-NR2B9c-Cl (20 mM histidine, 120 mM trehalose) versus TAT-NR2B9c-Ac (saline) at 11 months**

Peak (RRT)	NA-1 Chloride salt			NA-1-Ac in saline		
	T=11 months			T=11 months		
	-20°C	40°C	60°C	-20°C	40°C	60°C
RP-HPLC-TFA	0.899		0.1			
	0.93		0.18			
	0.95		0.16			0.27
	0.97		0.1			0.17
	0.99		0.29	0.38		0.22
	1	98.57	98.14	95.49	98.57	96.48
	1.02	1.18	1.09	1.42	1.14	1.8
	1.03	0.07	0.09	0.34	0.09	
	1.05			0.05	0.17	0.51
	1.06			0.15		0.06
	1.07	0.18	0.36	1.05	0.2	0.27
	1.08					0.08
	1.09					0.16
	1.1					0.06
	1.11					0.28
	1.12			0.12		0.33
	1.13					0.41
	1.15					3.49
	1.16					0.42
	1.17					0.16
	1.18					0.26
	1.19					0.1
	1.2					0.23
	1.22					0.26
	1.23					0.19
	1.24					0.3
	1.26					0.25
	1.261					0.34
	1.34					0.34
RP-HPLC-MSA	NA-1 Chloride salt	NA-1-Ac in saline				
	0.52					0.13
	0.87		0.13			
	0.91	0.05	0.2			0.23
	0.94	0.09	0.34			0.29
	0.98	0.1	0.12	0.21	0.1	0.12
	1	99.3	98.71	95.34	99.32	97.08
	1.02	0.29	0.24	0.61	0.24	0.28
	1.04	0.07	0.12		0.08	0.11
	1.06	0.25	0.48	1.48		
	1.07		0.06	0.25	0.25	1.03
	1.09		0.08	0.26		6.36
	1.1					0.45
	1.12					3.02
	1.14			0.17		0.27
	1.15					0.05
	1.16			0.11		0.23
	1.19					0.53
	1.2					0.26
	1.23		0.05	0.24		0.33
	1.24					0.1
	1.25			0.18		0.06
	1.26					0.59
	1.27					0.05
	1.33					0.44
	1.35					3.18

[00141] Table 27 shows the relative area of each peak observed in each HPLC assay at each temperature after 1 month of storage and at each relative retention time (peak identity) for direct

comparison. For both formulations and methods, the starting purities are very similar (98% for TAT-NR2B9c-Cl vs 97.93% for TAT-NR2B9c-Ac by the TFA method, and 99.3% vs 99.13% for the methanesulfonic acid (MSA) method. Looking at the 60°C data, the TAT-NR2B9c-Cl histidine trehalose composition is substantially more stable than the TAT-NR2B9c saline formulation by both methods. For the TFA method after 1 month of storage at 60°C, the TAT-NR2B9c-Cl salt retains 98.6% of the main peak whereas the TAT-NR2B9c-Ac saline formulation only retains 96.8% of the starting material. For the MSA method, the difference is even more striking, where the TAT-NR2B9c-Cl salt retains 99.4% of its starting material whereas the TAT-NR2B9c-Ac saline formulation only retains 97.2% of its starting material.

[00142] Table 28 shows the relative area of each peak observed in each HPLC assay at in the same samples after 11 months at the different storage temperatures. These data support the improved stability of the NA-1-Cl salt formulation versus the NA-1-Ac formulation in chloride. Comparing the area of the main NA-1 peaks in the TFA assay at 40°C, which is the accelerated condition by ICH guidance to support room temperature storage of a lyophilized drug, the NA-1-Cl retains 98.14% purity from a starting purity of 98.58, while the NA-1-Ac in saline has dropped from 98.57 pure to 96.48, which is below the purity specification of 97% and would not be considered stable after about a year. The same trend is observed for the MSA assay from 99.3% pure to 98.71 pure for NA-1-Cl and 97.08 for NA-1-Ac in saline. Examining the 60°C purity results after 11 months (Table 28), the differences are significantly more profound, with NA-1-Cl being significantly more stable than NA-1-Ac

[00143] From a clinical standpoint, example purity limits for a drug for humans may be 97% purity with no uncharacterized impurity over 0.5% at the rated storage condition. Using the Arrhenius equation, we can use the 40°C and 60°C stability data to predict the drop in purity of the main peak or the growth of the observed impurities at different storage temperatures (e.g., 25°C or 37°C versus the observed 40°C or 60°C data). Assuming that the drug would be stored at ambient temperature, it would be useful to demonstrate stability at 37°C because there would be many environments without refrigeration where the ambient temperature in the summer could be in this range. Assuming a purity requirement of 97.0% at 37°C, and using the representative stability data from the TFA assay for main peak purity because it is the most sensitive (i.e., shows the biggest decline in purity at 40°C and 60°C), the saline formulation would be predicted to have a shelf life of 29.8 months (or a little over 2 years), whereas the TAT-NR2B9c-Cl

formulation would have a shelf life of ~500 months, or approximately 41 years. This is a significant improvement in stability.

[00144] From the standpoint of the growth of the largest impurity (aside from the impurity at relative retention time (RTT) 1.02 by the TFA method which is an identified impurity), the largest impurity growth after 1 month for the TAT-NR2B9c-Cl formulation is 0.17 to 0.43 (RRT 0.99 by the TFA method), whereas the largest impurity growth for the TAT-NR2B9c-Ac saline formulation is 0.05-0.72 (1.13 RRT by the TFA method). Assuming the impurity limit above as 0.5% at 37<sup>0</sup>C, and using the Arrhenius equation along with the 40C and 60C data from each of these impurities, the saline formulation is predicted to have a shelf life of ~ 4.8 months at 37<sup>0</sup>C whereas the shelf life of the TAT-NR2B9c-Cl composition is predicted to be >10 years. Thus, from either the standpoint of the total level of TAT-NR2B9c or the growth of the largest impurity, the TAT-NR2B9c-Cl composition is a significant improvement over the saline formulation.

**Example 9: TAT-NR2B9c-Cl is more stable than TAT-NR2B9c-Ac in Histidine, Trehalose formulations**

[00145] TAT-NR2B9c-Cl and TAT-NR2B9c-Ac were both formulated at 90 mg/mL in 20 mM Histidine, 120 mM trehalose pH 6.5. Three milliliter aliquots (270 mg) of each were lyophilized under the same program as presented supra, and on completion were placed into constant temperature and humidity incubators at -20<sup>0</sup>C (control), 40<sup>0</sup>C and 60<sup>0</sup>C. After 4 weeks, the stability of each formulation was tested using two orthogonal HPLC methods – one with TFA as the carrier and one with MSA as the carrier.

[00146] Table 29 shows the relative area of each peak observed in each of the two HPLC assays at each temperature after 1 month of storage and at each relative retention time (RRT; peak identity) for direct comparison. The left panel represents the TAT-NR2B9c-Ac formulation and the right panel shows the results of the TAT-NR2B9c-Cl salt formulation. The peak at an RRT of 1 corresponds to the intact TAT-NR2B9c peptide in each assay and column. For both formulations and methods, the starting purities are very similar (98% for TAT-NR2B9c-Cl vs 98.3% for TAT-NR2B9c-Ac by the TFA method, and 99.3% vs 99.2% respectively for the MSA method). Looking at the 60<sup>0</sup>C data, the TAT-NR2B9c-Cl composition is substantially more stable than the TAT-NR2B9c-Ac formulation by both methods. For the TFA method after 1

month of storage at 60<sup>0</sup>C, the TAT-NR2B9c-Cl salt retains 98.6% of the main peak (96.64% divided by 98% starting) whereas the TAT-NR2B9c-Ac saline formulation only retains 96% of the starting material (94.44% divided by 98.3% starting purity). Form the MSA method, the difference is even more striking, where the TAT-NR2B9c-Cl salt retains 99.4% of its starting material (98.68%/99.3%) whereas the TAT-NR2B9c-Ac saline formation only retains 95.6% of its starting material (94.81%/99.2%). When one looks at the largest impurities for either composition, it is clear that for both the 40<sup>0</sup>C and 60<sup>0</sup>C accelerated stability conditions that the TAT-NR2B9c-acetate salt has larger impurities and is thus less stable. The chloride salt of TAT-NR2B9c is surprisingly more stable than the acetate salt under identical conditions.

[00147] Table 30 shows the relative area of each peak observed in each HPLC assay at in the same samples after 11 months at the different storage temperatures. These data support the improved stability of the NA-1-Cl salt formulation versus the NA-1-Ac salt when formulated in the exact same buffer (20 mM Histidine/120 mM Trehalose pH 6.5). Comparing the area of the main NA-1 peaks in the TFA assay at 40<sup>0</sup>C, which is the accelerated condition by ICH guidance to support room temperature storage of a lyophilized drug, the NA-1-Cl retains 98.14% purity from a starting purity of 98.58, while the NA-1-Ac in saline has dropped from 98.57 pure to 95.91, which is below the purity specification of 97% and would not be considered stable. The same trend is observed for the MSA assay from 99.3% pure to 98.71 pure for NA-1-Cl and 96.85% for NA-1-Ac in saline. Examining the 60<sup>0</sup>C purity results after 11 months (Table 30), the differences are significantly more profound, with NA-1-Cl being significantly more stable than NA-1-Ac (~95% pure for both assays for the chloride salt vs ~83% pure for the acetate salt). Thus, the NA-1 chloride salt is predicted to be surprisingly and significantly more stable than the acetate salt in the same buffer.

**Table 29: Stability of TAT-NR2B9c-Ac versus TAT-NR2B9c-Cl lyophilized in 20 mM Histidine 120 mM Trehalose pH 6.5 at 4 weeks**

RT	T=4 weeks		
	RT		
	-20°C	40°C	60°C
0.86			
0.88			
0.9			
0.93			
0.95			
0.97	0.06		
0.98			
0.99	0.58	0.56	
1	97.19	94.44	
1.02	1.52	2.18	
1.03	0.12	0.13	
1.04	0.18	0.71	
1.05			
1.06	0.07	0.37	
1.07	0.23	0.36	
1.08		0.16	
1.09		0.15	
1.1		0.18	
1.11		0.21	
1.12			
1.13	0.09	0.75	
1.14			
1.26			
1.34			
1.36			
1.4			
1.48			
0.77			
0.94		0.09	
0.98	0.12	0.19	
0.99	0.7	0.6	
1	98.11	94.81	
1.02	0.34	0.38	
1.03	0.1	0.17	
1.04			
1.06	0.4	1.46	
1.07			
1.08	0.14	0.64	
1.1		0.17	
1.12		0.14	
1.13		0.06	
1.14			
1.15		0.19	
1.16			
1.17		0.09	
1.18		0.07	
1.2			
1.23		0.17	
1.24		0.18	
1.27	0.08	0.59	
1.3			

RT	T=4 weeks		
	RT		
	-20°C	40°C	60°C
0.86			
0.88			
0.9			0.11
0.93			
0.95			
0.97			0.07
0.98			
0.99	0.17	0.29	0.43
1	98	97.78	96.84
1.02	1.27	1.22	1.36
1.03	0.11	0.11	0.16
1.04			
1.05	0.08	0.07	0.09
1.06			
1.07	0.32	0.24	0.46
1.08			
1.09			0.06
1.1		0.11	0.09
1.11	0.16		0.09
1.12		0.11	
1.13		0.06	
1.14			0.09
1.26			
1.34			
1.36			
1.4			
1.48			
0.77			
0.94			0.07
0.98	0.11	0.11	0.15
0.99			
1	99.3	99.14	98.66
1.02			
1.03	0.27	0.31	0.3
1.04	0.07	0.06	0.09
1.06	0.25	0.28	0.35
1.07		0.12	0.09
1.08			
1.1			0.07
1.12			
1.13			
1.14			
1.15			
1.16			
1.17			
1.18			
1.2			
1.23			
1.24			
1.27			
1.3			

**Table 30: Stability of TAT-NR2B9c-Ac versus TAT-NR2B9c-Cl lyophilized in 20 mM Histidine 120 mM Trehalose pH 6.5 after 11 months**

Peak (RT)	NA-1 250 mM His, 120 mM Trehalose pH 6.5			NA-1 Chloride salt stability data		
	T=11 months			T=11 months		
	-20°C	40°C	60°C	-20°C	40°C	60°C
RP-HPLC-TFA	0.86		0.12	0.52		
	0.88			0.17		
	0.899			0.15		0.1
	0.93					0.18
	0.95			0.14		0.16
	0.97			0.19		0.1
	0.99		0.37	0.63	0.29	0.38
	1	98.47	95.91	83.08	98.57	98.14
	1.02	1.21	1.93	3.77	1.18	1.09
	1.03	0.08			0.07	0.09
	1.05	0.05	0.57	3.45	0.05	0.17
	1.06		0.07	0.19		0.15
	1.07	0.19	0.31	0.78	0.18	0.36
	1.08		0.11	0.39		1.05
	1.09		0.07	0.27		
	1.1		0.07	0.31		
	1.12		0.06	0.29		0.12
	1.13		0.41	2.5		
	1.15			0.19		
	1.17			0.2		
	1.2			0.11		
	1.22			0.12		
	1.23			0.12		
	1.25			0.12		
RP-HPLC-MSA	NA-1 250 mM His, 120 mM Trehalose pH 6.5			NA-1 Chloride salt		
	0.77		0.08	0.48		
	0.8			0.14		
	0.87					0.13
	0.91			0.15	0.05	0.2
	0.94		0.05	0.14	0.09	0.34
	0.945			0.22		
	0.98	0.11	0.23	0.85	0.1	0.12
	1	99.23	96.85	82.73	99.3	98.71
	1.02	0.32	0.35	0.77	0.29	0.24
	1.04	0.08	0.11	0.77	0.07	0.12
	1.06	0.26	1.07	5.05	0.25	0.48
	1.07					0.06
	1.09		0.36	3.42		0.08
	1.1		0.08	0.41		
	1.12		0.07	0.32		
	1.14			0.28		0.17
	1.15		0.09	0.32		
	1.16					0.11
	1.19			0.27		
	1.23		0.07	0.37	0.05	0.24
	1.24			0.22		
	1.25					0.18
	1.26			0.19		
	1.27		0.38	2.47		
	1.35			0.12		

1. A chloride salt of a peptide which is TAT-NR2B9c (SEQ ID NO:6) or differs from TAT-NR2B9c by up to 5 amino acid substitutions, insertions or deletions.
2. The chloride salt of claim 1, which is TAT-NR2B9c.
3. The chloride salt of claim 1, prepared by exchanging trifluoroacetate for chloride in a trifluoroacetate salt of TAT-NR2B9c.
4. The chloride salt of claim 1, prepared by exchanging trifluoroacetate for acetate and then acetate for chloride starting from a trifluoroacetate salt of TAT-NR2B9c.
5. The chloride salt of claim 1, wherein greater than 99% of anions in the salt are chloride.
6. A prelyophilized formulation comprising the chloride salt as defined in any preceding claim, a buffer and a sugar.
7. The prelyophilized formulation of claim 6, wherein the chloride salt is a chloride salt of TAT-NR2B9c.
8. The prelyophilized formulation of claim 6 or 7, wherein the buffer is histidine and the sugar is trehalose and the pH is 6-7.
9. The prelyophilized formulation of claims 6-8 wherein acetate and trifluoroacetate each comprise less than 1% of anions by weight in the formulation.
10. The prelyophilized formulation of claim any of 6-8, wherein acetate and trifluoroacetate each comprise less than 0.1% by weight of anions in the formulation.
11. The prelyophilized formulation of any of claims 6-10, wherein the chloride salt of the peptide is at a concentration of 70-120 mg/ml, the histidine is at a concentration of 15-100 mM, and the trehalose is at a concentration of 80-160 mM.
12. The prelyophilized formulation of claim 11, wherein the chloride salt of the peptide is at a concentration of 70-120 mg/ml, the histidine is at a concentration of 20-100 mM, and the trehalose is at a concentration of 100-140 mM.

13. The prelyophilized formulation of any of claims 6-10, wherein the Tat-NR2B9c is at a concentration of 70-120 mg/ml, the concentration of histidine 20-50 mM, and the concentration of trehalose is 100-140 mM.

14. The prelyophilized formulation of any of claim 6-10, wherein the concentration of histidine is 20 mM and the concentration of trehalose is 100-200 mM, preferably 120 mM and the concentration of TAT-NR2B9c is 90 mg/ml.

15. A lyophilized formulation prepared by lyophilizing the prelyophilized formulation of any of claims 1-14.

16. The lyophilized formulation of claim 14, wherein acetate and trifluoroacetate each comprise less than 1% by weight of anions in the formulation.

17. The lyophilized formulation of claim 14, wherein acetate and trifluoroacetate each comprise less than 0.1% by weight of anions in the formulation.

18. A reconstituted formulation prepared by combining the lyophilized formulation of any of claims 6-17 with an aqueous solution.

19. The reconstituted formulation of claim 16, wherein the aqueous solution is water or normal saline.

20. The reconstituted formulation of claim 16, wherein the volume of the reconstituted formulation is 3-6 times the volume of the prelyophilized formulation.

21. A reconstituted formulation comprising TAT-NR2B9c at concentration of 15-25 mg/ml, a buffer and a sugar.

22. The reconstituted formulation of claim 21, wherein the buffer is histidine at a concentration of 4-20 mM and the sugar is trehalose at a concentration of 20-30 mM and the pH is 6-7.

23. The reconstituted formulation of claim 22 wherein acetate and trifluoroacetate each comprise less than 1% by weight of anions in the formulation.

24. The reconstituted formulation of claim 22, wherein acetate and trifluoroacetate each comprise less than 0.1% by weight of anions in the formulation.

25. A method of preparing a formulation, comprising

storing a lyophilized formulation sample according to any of claims 6-17 for at least a week at a temperature of at least 20°C; and  
reconstituting the lyophilized formulation.

26. The method of claim 25, wherein the lyophilized formulation is reconstituted in water.

27. The method of claim 25, wherein the lyophilized formulation is reconstituted in saline.

28. The method of claim 25, further comprising administering the reconstituted formulation, optionally after further dilution in normal saline, to a patient.

29. The method of claim 28, wherein the formulation is stored for at least a year.

30. The method of claim 29, wherein the storage is at ambient temperature.

31. The method of claim 30, wherein the storage includes periods in which the temperature exceeds 37°C.

32. The method of claim 25, wherein the patient has stroke or traumatic injury to the CNS.

33. The method of claim 25, wherein the lyophilized sample is stored in an ambulance.

34. The method of claim 25, wherein the patient has a subarachnoid hemorrhage.

35. The method of claim 25, wherein the patient is undergoing endovascular repair for an aneurysm.

1/7




FIG. 1

2/7

A




Figure 8. Plot of Purity Results, MSA Method (Ordered by pH)

B




FIG. 2A, B

3/7





FIG. 3


4/7

FIG. 4A, B




5/7

FIG. 5A, B





6/7

FIG. 6A, B




7/7

A



Small scale 4 NA-1

B



Formulations 1-3 from small scale 6

FIG. 7A, B

**INTERNATIONAL SEARCH REPORT**

International application No.  
**PCT/IB2015/053995**

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC: **C07K 19/00** (2006.01), **A61K 38/16** (2006.01), **A61K 9/19** (2006.01), **A61P 9/10** (2006.01),  
**C07K 14/16** (2006.01), **C07K 14/705** (2006.01), **C07K 7/06** (2006.01), **C07K 7/08** (2006.01)

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC: **C07K 19/00** (2006.01), **A61K 38/16** (2006.01), **A61K 9/19** (2006.01), **A61P 9/10** (2006.01), **C07K 14/16** (2006.01),  
**C07K 14/705** (2006.01), **C07K 7/06** (2006.01), **C07K 7/08** (2006.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

Canadian Patent Database, Questel Orbit, PubMed, Google Scholar, Google Patent, Google  
Keywords: Tat-NR2B9c, chloride, salt, lyophil\*

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2012/156308 A1 (BACH , A. ET AL.) 22-November-2012 See entire document, page 37 last paragraph	1-5, 15, 16a, 17a, 18a, 16b, 17b, 22-32
Y		6-14, 18b, 19-21
X	WO 2010/144721 A2 (TYMIANSKI, M. ET AL.) 16-December-2010 See entire document	1-5, 15, 16a, 17a, 18a, 16b, 17b, 22-32
Y		6-14, 18b, 19-21

Further documents are listed in the continuation of Box C.

See patent family annex.

* “A” document defining the general state of the art which is not considered to be of particular relevance	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
“E” earlier application or patent but published on or after the international filing date	“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
“O” document referring to an oral disclosure, use, exhibition or other means	“&” document member of the same patent family
“P” document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
01 September 2015 (01-09-2015)

Date of mailing of the international search report  
01 September 2015 (01-09-2015)

Name and mailing address of the ISA/CA  
Canadian Intellectual Property Office  
Place du Portage I, C114 - 1st Floor, Box PCT  
50 Victoria Street  
Gatineau, Quebec K1A 0C9  
Facsimile No.: 001-819-953-2476

Authorized officer  
Stephen Misener (819) 934-4548

**INTERNATIONAL SEARCH REPORT**

International application No.  
**PCT/IB2015/053995**

**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 7,060,268 B2 (ANDYA, J. ET AL.) 13-June-2006 See entire document	6-14, 18b, 19-21
P, X	WO 2014/085349 A1 (GARMAN, J.D.) 5-June-2014 See entire document	18b, 19-21

**INTERNATIONAL SEARCH REPORT**

International application No.  
**PCT/IB2015/053995**

**Box No. II****Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III****Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

The claims are directed to a plurality of inventive concepts as follows:

Group A - Claims 1-15, 16a, 17a, 18a, 16b, 17b, and 22-32 are directed to a chloride salt of the TAT-NR2B9c peptide; and  
Group B - Claims 18b-21 are directed to a reconstituted formulation of TAT-NR2B9c at concentration of 15-25 mg/ml, a buffer and a sugar.

The claims must be limited to one inventive concept as set out in Rule 13 of the PCT.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
**PCT/IB2015/053995**

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO2012156308A1	22 November 2012 (22-11-2012)	WO2012156308A1 AU2012257774A1 CA2833515A1 CN103533949A EP2707014A1 EP2707014B1 IL228893D0 JP2014514365A KR20140038435A MX2013013146A SG194717A1 US2014094415A1	22 November 2012 (22-11-2012) 07 November 2013 (07-11-2013) 22 November 2012 (22-11-2012) 22 January 2014 (22-01-2014) 19 March 2014 (19-03-2014) 17 June 2015 (17-06-2015) 31 December 2013 (31-12-2013) 19 June 2014 (19-06-2014) 28 March 2014 (28-03-2014) 27 May 2014 (27-05-2014) 30 December 2013 (30-12-2013) 03 April 2014 (03-04-2014)
WO2010144721A2	16 December 2010 (16-12-2010)	WO2010144721A2 WO2010144721A3 AU2010258664A1 AU2010258664B2 CA2765169A1 CN102458441A EP2440230A2 EP2440230A4 JP2012530057A US2012269733A1 US8940699B2 US2015202253A1	16 December 2010 (16-12-2010) 21 April 2011 (21-04-2011) 12 January 2012 (12-01-2012) 28 May 2015 (28-05-2015) 16 December 2010 (16-12-2010) 16 May 2012 (16-05-2012) 18 April 2012 (18-04-2012) 28 May 2014 (28-05-2014) 29 November 2012 (29-11-2012) 25 October 2012 (25-10-2012) 27 January 2015 (27-01-2015) 23 July 2015 (23-07-2015)
US7060268B2	13 June 2006 (13-06-2006)	US2003202972A1 AR003468A1 AR003969A1 AR074517A2 AT225185T AU6638196A AU715338B2 AU6599296A AU716785B2 BR9609743A CA2226575A1 CA2226575C CA2226624A1 CA2226624C CA2745743A1 CN1191490A CN1151842C CN1539505A CN100360184C CN101172099A CN101172099B CN101172100A CN102416176A DE69624116D1 DE69624116T2 DE69624116T3 DK0841946T3 DK0841946T4 DK1516628T3 DK2275119T3	30 October 2003 (30-10-2003) 05 August 1998 (05-08-1998) 30 September 1998 (30-09-1998) 26 January 2011 (26-01-2011) 15 October 2002 (15-10-2002) 26 February 1997 (26-02-1997) 20 January 2000 (20-01-2000) 26 February 1997 (26-02-1997) 09 March 2000 (09-03-2000) 02 March 1999 (02-03-1999) 13 February 1997 (13-02-1997) 18 October 2011 (18-10-2011) 13 February 1997 (13-02-1997) 16 July 2013 (16-07-2013) 13 February 1997 (13-02-1997) 26 August 1998 (26-08-1998) 02 June 2004 (02-06-2004) 27 October 2004 (27-10-2004) 09 January 2008 (09-01-2008) 07 May 2008 (07-05-2008) 15 February 2012 (15-02-2012) 07 May 2008 (07-05-2008) 18 April 2012 (18-04-2012) 07 November 2002 (07-11-2002) 18 June 2003 (18-06-2003) 09 July 2009 (09-07-2009) 10 February 2003 (10-02-2003) 16 February 2009 (16-02-2009) 08 September 2013 (08-09-2013) 11 November 2013 (11-11-2013)

Continued on supplemental sheet

## INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/IB2015/053995**

EP0841946A1	20 May 1998 (20-05-1998)
EP0841946B1	02 October 2002 (02-10-2002)
EP0841946B2	15 October 2008 (15-10-2008)
EP0845997A1	10 June 1998 (10-06-1998)
EP1516628A1	23 March 2005 (23-03-2005)
EP1516628B1	21 August 2013 (21-08-2013)
EP2275119A1	19 January 2011 (19-01-2011)
EP2275119B1	25 September 2013 (25-09-2013)
ES2186796T3	16 May 2003 (16-05-2003)
ES2186796T5	01 April 2009 (01-04-2009)
ES2434840T3	17 December 2013 (17-12-2013)
ES2435462T3	19 December 2013 (19-12-2013)
HK1070283A1	21 February 2014 (21-02-2014)
HK1117075A1	30 November 2012 (30-11-2012)
HK1152876A1	14 February 2014 (14-02-2014)
IL122733D0	16 August 1998 (16-08-1998)
IL122733A	13 September 2001 (13-09-2001)
IL122910D0	16 August 1998 (16-08-1998)
IL122910A	23 May 2002 (23-05-2002)
JPH11510172A	07 September 1999 (07-09-1999)
JP4153560B2	24 September 2008 (24-09-2008)
JP2007238628A	20 September 2007 (20-09-2007)
JP5043506B2	10 October 2012 (10-10-2012)
JP2007217430A	30 August 2007 (30-08-2007)
JP5043507B2	10 October 2012 (10-10-2012)
JPH11510170A	07 September 1999 (07-09-1999)
JP2011256205A	22 December 2011 (22-12-2011)
JP2011256206A	22 December 2011 (22-12-2011)
JP2014148555A	21 August 2014 (21-08-2014)
MX9800684A	30 April 1998 (30-04-1998)
MX9800760A	30 April 1998 (30-04-1998)
NO980335D0	26 January 1998 (26-01-1998)
NO980335A	26 March 1998 (26-03-1998)
NO323557B1	11 June 2007 (11-06-2007)
NO323557B3	11 June 2007 (11-06-2007)
NO20070121I	29 November 2007 (29-11-2007)
NZ313503A	28 January 2000 (28-01-2000)
NZ500539A	30 November 2001 (30-11-2001)
PT841946E	28 February 2003 (28-02-2003)
PT1516628E	24 September 2013 (24-09-2013)
PT2275119E	21 November 2013 (21-11-2013)
RU2229288C2	27 May 2004 (27-05-2004)
RU2497500C2	10 November 2013 (10-11-2013)
RU2013141049A	20 March 2015 (20-03-2015)
SI1516628T1	30 October 2013 (30-10-2013)
SI2275119T1	31 December 2013 (31-12-2013)
US6267958B1	31 July 2001 (31-07-2001)
US2001014326A1	16 August 2001 (16-08-2001)
US6685940B2	03 February 2004 (03-02-2004)
US6821515B1	23 November 2004 (23-11-2004)
US2006275306A1	07 December 2006 (07-12-2006)
US7692609B2	23 March 2010 (23-03-2010)
US2004197326A1	07 October 2004 (07-10-2004)
US2006099201A1	11 May 2006 (11-05-2006)
US2007020256A1	25 January 2007 (25-01-2007)
US2009087426A1	02 April 2009 (02-04-2009)
US2010158899A1	24 June 2010 (24-06-2010)
US2011236383A1	29 September 2011 (29-09-2011)
US2011311520A1	22 December 2011 (22-12-2011)
US2013224185A1	29 August 2013 (29-08-2013)
WO9704801A1	13 February 1997 (13-02-1997)
WO9704807A1	13 February 1997 (13-02-1997)
ZA9606075A	19 January 1998 (19-01-1998)
ZA9606240A	23 January 1998 (23-01-1998)

Continued on supplemental sheet

INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/IB2015/053995**

WO2014085349A1	05 June 2014 (05-06-2014)	WO2014085349A1 AU2013352437A1 CA2892965A1 US2014162957A1	05 June 2014 (05-06-2014) 09 July 2015 (09-07-2015) 05 June 2014 (05-06-2014) 12 June 2014 (12-06-2014)
----------------	---------------------------	---	--